var title_f43_5_44112="Open book pelvic fracture";
var content_f43_5_44112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Open book pelvic fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This open-book pelvis fracture was sustained in a motor vehicle collision. The fracture was associated with a posterior urethral injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Runyon, MD, FAAEM.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44112=[""].join("\n");
var outline_f43_5_44112=null;
var title_f43_5_44113="Flat adenoma indigo carmine";
var content_f43_5_44113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chromoendoscopy with indigo carmine of a colon adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution endoscopic image of a small flat colon adenoma in a patient with familial adenomatous polyposis after spraying with indigo carmine. The indigo carmine is not absorbed and collects in the crevices between epithelial cells thereby enhancing the mucosal details.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis Giardiello, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44113=[""].join("\n");
var outline_f43_5_44113=null;
var title_f43_5_44114="Construction of an ostomy - skin incision";
var content_f43_5_44114=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F79596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F79596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Construction of an ostomy - skin incision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 528px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts making&nbsp;the skin incision on the abdominal wall with electrocautery in preparation for constructing an ostomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44114=[""].join("\n");
var outline_f43_5_44114=null;
var title_f43_5_44115="Bimatoprost: Drug information";
var content_f43_5_44115=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bimatoprost: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/57/42900?source=see_link\">",
"    see \"Bimatoprost: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Latisse&reg;;",
"     </li>",
"     <li>",
"      Lumigan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Latisse&reg;;",
"     </li>",
"     <li>",
"      Lumigan&reg;;",
"     </li>",
"     <li>",
"      Lumigan&reg; RC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F141334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma;",
"     </li>",
"     <li>",
"      Prostaglandin, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F141313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Open-angle glaucoma or ocular hypertension: Ophthalmic: Instill 1 drop into affected eye(s) once daily in the evening; do not exceed once-daily dosing (may decrease IOP-lowering effect). If used with other topical ophthalmic agents, separate administration by at least 5 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotrichosis of the eyelashes: Ophthalmic, topical: Place one drop on applicator and apply evenly along the skin of the upper eyelid at base of eyelashes once daily at bedtime; repeat procedure for second eye (use a clean applicator).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F141314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F141290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Latisse&reg;: 0.03% (3 mL, 5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lumigan&reg;: 0.01% (2.5 mL, 5 mL, 7.5 mL); 0.03% (2.5 mL, 5 mL, 7.5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F141277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F141293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Latisse&reg;: Remove make-up and contact lenses prior to application; ensure face is clean. Apply with the sterile applicator provided only; do not use other brushes or applicators. Use a tissue or cloth to blot any excess solution on the outside of the upper eyelid margin; do not apply to lower eyelash line. Do not reuse applicators; use new applicator for second eye. Applying more than once nightly will not increase eyelash growth; eyelash growth is expected to return to baseline when therapy is discontinued. May reinsert contacts 15 minutes after application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumigan&reg;: May be used with other eye drops to lower intraocular pressure. If using more than one ophthalmic product, wait at least 5 minutes in between application of each medication. Remove contact lenses prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F141291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; hypotrichosis treatment of the eyelashes",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F141332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions and percentages are for Lumigan&reg; unless noted:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Ocular: Conjunctival hyperemia (25% to 45%; Latisse&reg;: &lt;4%), growth of eyelashes, ocular pruritus (&gt;10%; Latisse&reg;: &lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin hyperpigmentation (Latisse&reg;: &lt;4%), abnormal hair growth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests abnormal (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Dry eyes (1% to 10%; Latisse&reg;: &lt;4%), erythema (eyelid/periorbital region; 1% to 10%; Latisse&reg;: &lt;4%), irritation (1% to 10%; Latisse&reg;: &lt;4%), allergic conjunctivitis, asthenopia, blepharitis, burning, cataract, conjunctival edema, conjunctival hemorrhage, discharge, eyelash darkening, foreign body sensation, iris pigmentation increased (may be delayed), pain, photophobia, pigmentation of periocular skin, superficial punctate keratitis, tearing, visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infections (10% [primarily colds and upper respiratory tract infections])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Hypertension, iritis, macular edema, madarosis, trichorrhexis, uveitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F141296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Latisse&reg;: Hypersensitivity to bimatoprost or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumigan&reg;: There are no contraindications listed in the manufacturer&rsquo;s prescribing information.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F141281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions, has caused bacterial keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: May permanently change/increase brown pigmentation of the iris, the eyelid skin, and eyelashes. In addition, may increase the length and/or number of eyelashes (may vary between eyes); changes occur slowly and may not be noticeable for months or years. Long-term consequences and potential injury to eye are not known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with intraocular inflammation, aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with risk factors for macular edema. Safety and efficacy have not been determined for use in patients with angle-closure-, inflammatory-, or neovascular glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Contains benzalkonium chloride which may be adsorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not recommended for use in pediatrics &lt;16 years of age due to potential concerns regarding long-term use and hyperpigmentation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latisse&reg;: Patients receiving medications to reduce intraocular pressure should consult their healthcare provider prior to using; may interfere with desired reduction of intraocular pressure. Unintentional hair growth may occur on skin that has repeated contact with solution; apply to upper eyelid only, blot away excess.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F141285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Latanoprost: The concomitant use of Latanoprost and Bimatoprost may result in increased intraocular pressure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F141287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3187067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased gestation, decreased body weight, increased late resorptions, and increased mortality were observed in animal reproduction studies with oral doses achieving serum levels &gt;33 times human exposure.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F141316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16248960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if bimatoprost is excreted in breast milk. The manufacturer recommends that caution be exercised when administering bimatoprost to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F141298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Latisse External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.03% (3 mL): $124.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lumigan Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (5 mL): $251.27",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F141299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Latisse (AR, HK, SG);",
"     </li>",
"     <li>",
"      Lumigan (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, IE, IL, IN, IT, KP, MT, MX, MY, NL, NO, NZ, PA, PE, PH, PK, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Malena (PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F141280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a synthetic analog of prostaglandin with ocular hypotensive activity, bimatoprost decreases intraocular pressure by increasing the outflow of aqueous humor. Bimatoprost may increase the percent and duration of hairs in the growth phase, resulting in eyelash growth.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F141295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Reduction of IOP: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Maximum reduction of IOP: ~8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.67 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes oxidation, N-deethylation, and glucuronidation after reaching systemic circulation; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: ~45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: &le;10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&le;67%); feces (25%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8931 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-EFD95E538C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44115=[""].join("\n");
var outline_f43_5_44115=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141310\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141311\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141334\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141313\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141314\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141290\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141277\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141293\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141291\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141332\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141296\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141281\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298865\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141285\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141287\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3187067\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141316\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16248960\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141298\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141299\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141280\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141295\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8931\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8931|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/57/42900?source=related_link\">",
"      Bimatoprost: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_5_44116="Teriparatide (recombinant human parathyroid hormone (1-34)): Patient drug information";
var content_f43_5_44116=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Teriparatide (recombinant human parathyroid hormone (1-34)): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/22/6501?source=see_link\">",
"     see \"Teriparatide (recombinant human parathyroid hormone (1-34)): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Forteo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Forteo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700399",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Large doses of teriparatide in animals caused more bone cancer. Do not take this drug if you have Paget's disease, a rise in alkaline phosphatase, radiation therapy of bones, or growing bones.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to teriparatide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698200",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leg cramps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what your doctor has told you to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695645",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sit down before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of the solution not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3406276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For facts about storing this drug during travel go to: file://www.forteo.com/Pages/consumer_traveling.aspx",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11081 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44116=[""].join("\n");
var outline_f43_5_44116=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225837\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855044\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019601\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019603\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019602\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019607\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019608\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019610\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019605\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019606\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019611\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019612\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/22/6501?source=related_link\">",
"      Teriparatide (recombinant human parathyroid hormone (1-34)): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_5_44117="Tonic pupil";
var content_f43_5_44117=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tonic pupil",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/5/44117/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/5/44117/contributors\">",
"     Andrew G Lee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/5/44117/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/5/44117/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/5/44117/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/5/44117/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/5/44117/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tonic pupil, sometimes called Adie's tonic pupil or simply the Adie pupil, is the term used to denote a pupil with parasympathetic denervation that constricts poorly to light but reacts better to accommodation (near response), such that the initially larger Adie pupil becomes smaller than its normal fellow and remains tonically constricted, redilating very slowly when exposed to dark.",
"   </p>",
"   <p>",
"    Although the eponym credits Adie with its discovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44117/abstract/1\">",
"     1",
"    </a>",
"    ], the tonic pupil was originally described nearly synchronously by Adie, Morgan, Symonds, and Holmes in 1931 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44117/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tonic pupil is a common cause of anisocoria, or unequal pupils. The prevalence of the Adie's pupil is about two cases per 1000 population. Although patients of all ages are affected, the mean age is 32 years, and there is a female predominance (2.6:1) for the idiopathic variety (Adie's tonic pupil).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tonic pupil is the result of damage to the parasympathetic ciliary ganglion. The parasympathetic innervation to the iris and ciliary body travels with the third cranial nerve and synapses in the ciliary ganglion. After damage to the ciliary ganglion, reinnervation and up-regulation of the post-synaptic receptors occurs, a process known as denervation supersensitivity. The number of axons destined for the ciliary body, however, is about 30 times the number that supply the pupil. After denervation occurs, the reinnervation may be aberrant, and fibers formerly destined for the ciliary body now travel to the pupil (aberrant regeneration).",
"   </p>",
"   <p>",
"    Activation of the near response in this situation produces a better near reaction than light reaction (light-near dissociation of the pupils), and the reaction is tonic.",
"   </p>",
"   <p>",
"    Most cases of the tonic pupil are idiopathic and referred to as the Adie's tonic pupil. However, the tonic pupil can be caused by local disorders within the orbit affecting the ciliary ganglion including tumor, inflammation, trauma, surgery, or infection (",
"    <a class=\"graphic graphic_table graphicRef53885 \" href=\"mobipreview.htm?32/52/33612\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44117/abstract/6-45\">",
"     6-45",
"    </a>",
"    ]. Systemic autonomic neuropathies can also affect the ciliary ganglion and produce the tonic pupil. As an example, the Ross syndrome is a dysautonomia characterized by a triad of tonic pupil, hyporeflexia, and segmental anhidrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44117/abstract/16,38,43,45\">",
"     16,38,43,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The infectious and inflammatory causes of the tonic pupil are further expanded in the table (",
"    <a class=\"graphic graphic_table graphicRef60816 \" href=\"mobipreview.htm?30/49/31515\">",
"     table 2",
"    </a>",
"    ) as are the autonomic or peripheral neuropathic etiologies (",
"    <a class=\"graphic graphic_table graphicRef67360 \" href=\"mobipreview.htm?23/8/23691\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of the Adie's tonic pupil are as follows (",
"    <a class=\"graphic graphic_table graphicRef77357 \" href=\"mobipreview.htm?5/30/5611\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor or absent pupillary light reaction",
"     </li>",
"     <li>",
"      Segmental palsy of the sphincter",
"     </li>",
"     <li>",
"      Tonic pupillary near response with light-near dissociation",
"     </li>",
"     <li>",
"      Cholinergic supersensitivity of the denervated muscles",
"     </li>",
"     <li>",
"      Accommodation paresis (that tends to recover)",
"     </li>",
"     <li>",
"      Induced astigmatism at near and tonicity of accommodation",
"     </li>",
"     <li>",
"      Occasional \"ciliary cramp\" (accommodative spasm) with near work",
"     </li>",
"     <li>",
"      Occasional regional corneal anesthesia (trigeminal fibers in ciliary ganglion damaged)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main clinical question in the patient with anisocoria is deciding whether the larger pupil or the smaller pupil is the problem. The key differentiating signs are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The pupillary reaction to light",
"     </li>",
"     <li>",
"      The pupillary near response",
"     </li>",
"     <li>",
"      The amount of anisocoria in the light and in the dark",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Review of old photographs is useful for defining the duration of an anisocoria. Patients referred for pupil abnormalities should be told to bring as many old photographs of themselves as possible to the appointment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31206?source=see_link\">",
"     \"Approach to the patient with anisocoria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A pupil that reacts poorly to light is obviously the pathologic one, if one pupil is poorly reactive and the other pupil is normally reactive. In these circumstances, the anisocoria is generally less in the dark and more in the light (poor constriction of affected pupil). Patients with an impaired light reaction should be tested for a pupillary near response. A normal near response in the setting of an impaired or absent light response is termed light-near dissociation. This finding can be unilateral or bilateral. Bilateral light-near dissociation of the pupils is demonstrated, if the light reaction is poor and the near reaction is intact in both eyes. The table lists the causes of light-near dissociation (",
"    <a class=\"graphic graphic_table graphicRef60550 \" href=\"mobipreview.htm?2/32/2571\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The tonic pupil is distinguished from other causes of light-near dissociation by the tonicity of the near reaction. The tonic reaction is the result of iris sphincter supersensitivity to acetylcholine. The pupil is often irregular. When stimulated, the pupil response is strong and tonic, and relaxation is slow and sustained.",
"   </p>",
"   <p>",
"    Initially, there may be an isolated internal ophthalmoplegia, and in the acute stage there may be no reaction to light or near at all. This presentation may mimic pharmacologic dilation of the pupil. The diagnosis of a tonic pupil can usually be made on clinical grounds alone, with time, as the light-near dissociation and denervation supersensitivity develop. Some segments of the pupil may react normally (vermiform movements), while other segments may not react to light well or at all (sector paresis).",
"   </p>",
"   <p>",
"    Although the tonic pupil is usually larger than the uninvolved fellow eye, over time the pupil tends to become smaller (the \"little old Adie's\" pupil). About 20 percent of Adie's pupils are bilateral with a 4 percent incidence of bilateral involvement per year (",
"    <a class=\"graphic graphic_picture graphicRef73497 \" href=\"mobipreview.htm?26/9/26770\">",
"     picture 1",
"    </a>",
"    ). The key finding in the miotic long-standing Adie's pupil will be the poor light reaction and the tonic near response. Patients may have decreased deep tendon reflexes in the complete Holmes-Adie syndrome (",
"    <a class=\"graphic graphic_table graphicRef57952 \" href=\"mobipreview.htm?7/44/7883\">",
"     table 6",
"    </a>",
"    ), but most patients are otherwise asymptomatic.",
"   </p>",
"   <p>",
"    No further pharmacologic testing is typically necessary if the characteristic features of the tonic pupil are present (",
"    <a class=\"graphic graphic_figure graphicRef78432 \" href=\"mobipreview.htm?6/29/6611\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77357 \" href=\"mobipreview.htm?5/30/5611\">",
"     table 4",
"    </a>",
"    ). Otherwise, low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    (one-eighth percent to one-tenth percent) may be useful to demonstrate the cholinergic supersensitivity in the tonic pupil. After the administration of the dilute pilocarpine, a more miotic response will be seen compared with the fellow eye (",
"    <a class=\"graphic graphic_figure graphicRef78432 \" href=\"mobipreview.htm?6/29/6611\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Unfortunately, cholinergic supersensitivity is not uniformly present in tonic pupils (about 80 percent) and is not specific for postganglionic parasympathetic denervation. Both eyes should be tested, as some patients may respond to low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    , especially patients who have light colored irises [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44117/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supersensitivity has also been reported after preganglionic lesions of the third nerve. In addition, as stated previously, an acute Adie's tonic pupil may not have had time to develop postganglionic supersensitivity, and absent supersensitivity does not exclude the diagnosis in this setting. Because this presentation may mimic pharmacologic dilation, the patient should be followed over time to allow the more typical findings of tonic pupil to develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a defined etiology (eg, local orbital or known systemic autonomic neuropathy) for the tonic pupil do not generally require additional evaluation (",
"    <a class=\"graphic graphic_table graphicRef53885 \" href=\"mobipreview.htm?32/52/33612\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60816 \" href=\"mobipreview.htm?30/49/31515\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67360 \" href=\"mobipreview.htm?23/8/23691\">",
"     table 3",
"    </a>",
"    ). Likewise, no additional testing is necessary if the clinical or pharmacologic diagnosis of the typical Adie's tonic pupil is made.",
"   </p>",
"   <p>",
"    Symptoms or signs of gastrointestinal, cardiac, or segmental hypohidrosis and areflexia should prompt evaluation for systemic dysautonomia (eg, Ross syndrome) in patients with tonic pupils. Patients with unexplained bilateral tonic pupils should probably have serologic testing for syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44117/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .) In one series of 60 patients with tonic pupils, 5 of 29 had positive serologic tests for syphilis and in addition had bilateral tonic pupils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44117/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While syphilis may infrequently produce the tonic pupil, late syphilis is associated with the Argyll Robertson pupil. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26312?source=see_link\">",
"     \"Neurosyphilis\"",
"    </a>",
"    .) In addition to light-near dissociation, the Argyll Robertson pupil is typically miotic and irregular. However, Argyll Robertson pupils are not tonic. They constrict quickly to near and redilate quickly when removed from the near stimulus.",
"   </p>",
"   <p>",
"    Although classically described with neurosyphilis, other entities may produce pupillary light-near dissociation. These etiologies include diabetes, chronic alcoholism, encephalitis, multiple sclerosis, peripheral nerve disease, (eg, Charcot-Marie-Tooth), rare midbrain tumors, herpes zoster, neurosarcoidosis, and lymphocytic meningoradiculitis.",
"   </p>",
"   <p>",
"    Patients with light-near dissociation of the pupils in the setting of a third nerve palsy including aberrant regeneration of the third nerve or other dorsal midbrain signs should undergo neuroimaging, preferably magnetic resonance imaging of the brainstem with contrast. Patients with systemic autonomic neuropathies (eg, Ross syndrome) should undergo appropriate general neurologic and other testing as indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with a tonic pupil do not require any treatment. Patients with an underlying systemic cause for their tonic pupils should have treatment directed at their other autonomic neuropathies.",
"   </p>",
"   <p>",
"    Although patients with Adie's syndrome may complain of difficulty reading due to accommodative paresis, this usually improves spontaneously. Unequal power bifocal reading aids or a unilateral frosted bifocal segment may be necessary for patients with permanent accommodative paresis. Topical low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    may help with symptomatic patients but can precipitate ciliary spasm, induced myopia, cause brow ache, or worsen the appearance of the anisocoria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44117/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Adie's tonic pupil is benign, and most patients only require reassurance once the diagnosis is confirmed. Angle-closure glaucoma has been rarely reported secondary to the tonic pupil, once in association with plateau iris [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44117/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accommodative paresis tends to resolve spontaneously over several months. The pupil light reaction usually does not recover and may even become weaker over time with an increasing light-near dissociation. In some patients the pupil becomes smaller with time (\"little old Adie's\").",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tonic pupil results from parasympathetic denervation at the level of the ciliary ganglion and postganglionic nerves.",
"     </li>",
"     <li>",
"      The tonic pupil constricts poorly or not at all to light but reacts better to accommodation (near response), such that the initially larger tonic pupil becomes smaller than its normal fellow and remains tonically constricted, redilating very slowly when exposed to dark.",
"     </li>",
"     <li>",
"      Most cases of the tonic pupil are idiopathic and referred to as the Adie's tonic pupil (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above). However, the tonic pupil can be caused by local disorders within the orbit affecting the ciliary ganglion including tumor, inflammation, trauma, surgery, or infection.",
"     </li>",
"     <li>",
"      The tonic pupil is a common cause of anisocoria (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above). The main clinical question in the patient with anisocoria is deciding whether the larger pupil or the smaller pupil is the problem (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical approach'",
"      </a>",
"      above). The key differentiating signs are the pupillary reaction to light, the near response, and the amount of anisocoria in the light and in the dark.",
"     </li>",
"     <li>",
"      The tonic pupil is distinguished from other causes of light-near dissociation by the tonicity of the near reaction (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical approach'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In the acute stage, the tonic pupil may exhibit no reaction to light or near at all (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical approach'",
"      </a>",
"      above). This presentation may mimic pharmacologic dilation of the pupil.",
"     </li>",
"     <li>",
"      Pharmacologic testing is usually not necessary if the typical clinical features of the tonic pupil are present (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical approach'",
"      </a>",
"      above). Otherwise, low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      may be useful to demonstrate the cholinergic supersensitivity in the tonic pupil.",
"     </li>",
"     <li>",
"      Patients with a defined etiology for the tonic pupil do not generally require additional evaluation (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above). Likewise, no additional testing is necessary if the clinical or pharmacologic diagnosis of the typical Adie's tonic pupil is made.",
"     </li>",
"     <li>",
"      Patients with unexplained bilateral tonic pupils should probably have serologic testing for syphilis, and patients with light-near dissociation of the pupils in the setting of a third nerve palsy or other dorsal midbrain signs should undergo neuroimaging (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Most patients with a tonic pupil do not require any treatment (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above). Those who have an identified cause of tonic pupil should receive appropriate treatment directed at the underlying cause.",
"     </li>",
"     <li>",
"      The Adie's tonic pupil is benign, and most patients only require reassurance once the diagnosis is confirmed (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Prognosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bruyn GW, Gooddy W. Adie's syndrome. In: Neurological Eponyms, Koehler PJ, Bruyn GW, Pearce JMS (Eds), Oxford University Press, New York 2000. p.181.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/2\">",
"      Adie WJ. PSEUDO-ARGYLL ROBERTSON PUPILS WITH ABSENT TENDON REFLEXES: A BENIGN DISORDER SIMULATING TABES DORSALIS. Br Med J 1931; 1:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/3\">",
"      Morgan OG, Symonds CP. Internal Ophthalmoplegia with Absent Tendon-jerks. Proc R Soc Med 1931; 24:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/4\">",
"      Symonds CP. Internal ophthalmoplegia with absent tendon jerks. Proc R Soc Med 1931; 24:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/5\">",
"      Holmes G. Partial iridoplegia with symptoms of other diseases of the nervous system. Trans Ophthalmol Soc UK 1931; 51:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/6\">",
"      Thompson HS. Adie's syndrome: some new observations. Trans Am Ophthalmol Soc 1977; 75:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/7\">",
"      Leavitt JA, Wayman LL, Hodge DO, Brubaker RF. Pupillary response to four concentrations of pilocarpine in normal subjects: application to testing for Adie tonic pupil. Am J Ophthalmol 2002; 133:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/8\">",
"      Sakai T, Shikishima K, Mizobuchi T, et al. Bilateral tonic pupils associated with neurosyphilis. Jpn J Ophthalmol 2003; 47:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/9\">",
"      Fletcher WA, Sharpe JA. Tonic pupils in neurosyphilis. Neurology 1986; 36:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/10\">",
"      Kawana K, Okamoto F, Nose H, Oshika T. A case of angle closure glaucoma caused by plateau iris and adie's pupil. Am J Ophthalmol 2003; 135:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/11\">",
"      Leibovitch I, Kurtz S, Almog Y. Adie's tonic pupil-induced angle-closure glaucoma. Ophthalmologica 2002; 216:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/12\">",
"      Bachmeyer C, Zuber M, Dupont S, et al. Adie syndrome as the initial sign of primary Sj&ouml;gren syndrome. Am J Ophthalmol 1997; 123:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/13\">",
"      Bennett JL, Pelak VA, Mourelatos Z, et al. Acute sensorimotor polyneuropathy with tonic pupils and an abduction deficit: an unusual presentation of polyarteritis nodosa. Surv Ophthalmol 1999; 43:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/14\">",
"      Bowie EM, Givre SJ. Tonic pupil and sarcoidosis. Am J Ophthalmol 2003; 135:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/15\">",
"      Caputo AR, Mickey KJ, Guo S. A varicella-induced pupil abnormality. Pediatrics 1992; 89:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/16\">",
"      Chakravarty A, Mukherjee A, Roy D. Ross syndrome--a case documentation. Acta Neurol Scand 2003; 107:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/17\">",
"      Corridan PG, Laws DE, Morrell AJ, Murray PI. Tonic pupils and human parvovirus (B19) infection. J Clin Neuroophthalmol 1991; 11:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/18\">",
"      Cox TA, Goldberg RA, Rootman J. Tonic pupil and Czarnecki's sign following third nerve palsy. J Clin Neuroophthalmol 1991; 11:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/19\">",
"      Davies DR, Smith SE. Pupil abnormality in amyloidosis with autonomic neuropathy. J Neurol Neurosurg Psychiatry 1999; 67:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/20\">",
"      Foroozan R, Buono LM, Savino PJ, Sergott RC. Tonic pupils from giant cell arteritis. Br J Ophthalmol 2003; 87:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/21\">",
"      Foster RE, Kosmorsky GS, Sweeney PJ, Masaryk TJ. Horner's syndrome secondary to spontaneous carotid dissection with normal angiographic findings. Arch Ophthalmol 1991; 109:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/22\">",
"      Goldstein SM, Liu GT, Edmond JC, et al. Orbital neural-glial hamartoma associated with a congenital tonic pupil. J AAPOS 2002; 6:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/23\">",
"      Haider S. Tonic pupil in lymphomatoid granulomatosis. J Clin Neuroophthalmol 1993; 13:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/24\">",
"      Heger T, Kolling GH, Dithmar S. [Atypical tonic pupil as a complication of chickenpox infection]. Ophthalmologe 2003; 100:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/25\">",
"      Hodgkins PR, Luff AJ, Absolon MJ. Internal ophthalmoplegia--a complication of ocular varicella. Aust N Z J Ophthalmol 1993; 21:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/26\">",
"      Jacobson DM. A prospective evaluation of cholinergic supersensitivity of the iris sphincter in patients with oculomotor nerve palsies. Am J Ophthalmol 1994; 118:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/27\">",
"      Jacobson DM. Pupillary responses to dilute pilocarpine in preganglionic 3rd nerve disorders. Neurology 1990; 40:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/28\">",
"      Kardon RH, Corbett JJ, Thompson HS. Segmental denervation and reinnervation of the iris sphincter as shown by infrared videographic transillumination. Ophthalmology 1998; 105:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/29\">",
"      Kimber J, Mitchell D, Mathias CJ. Chronic cough in the Holmes-Adie syndrome: association in five cases with autonomic dysfunction. J Neurol Neurosurg Psychiatry 1998; 65:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/30\">",
"      Bruno MK, Winterkorn JM, Edgar MA, et al. Unilateral Adie pupil as sole ophthalmic sign of anti-Hu paraneoplastic syndrome. J Neuroophthalmol 2000; 20:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/31\">",
"      Lambert SR, Yang LL, Stone C. Tonic pupil associated with congenital neuroblastoma, Hirschsprung disease, and central hypoventilation syndrome. Am J Ophthalmol 2000; 130:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/32\">",
"      Mabuchi K, Yoshikawa H, Takamori M, et al. Pseudo-Argyll Robertson pupil of patients with spinocerebellar ataxia type 1 (SCA1). J Neurol Neurosurg Psychiatry 1998; 65:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/33\">",
"      Patel JI, Jenkins L, Benjamin L, Webber S. Dilated pupils and loss of accommodation following diode panretinal photocoagulation with sub-tenon local anaesthetic in four cases. Eye (Lond) 2002; 16:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/34\">",
"      Phillips PH, Newman NJ. Tonic pupil in a child. J Pediatr Ophthalmol Strabismus 1996; 33:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/35\">",
"      Purvin VA. Adie's tonic pupil secondary to migraine. J Neuroophthalmol 1995; 15:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/36\">",
"      Radziwill AJ, Steck AJ, Borruat FX, Bogousslavsky J. Isolated internal ophthalmoplegia associated with IgG anti-GQ1b antibody. Neurology 1998; 50:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/37\">",
"      Serra Mitjans M, Callejas P&eacute;rez MA, Valls Sol&eacute; J, et al. [Surgical treatment for compensatory hyperhidrosis in Adie syndrome]. Arch Bronconeumol 2004; 40:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/38\">",
"      Shin RK, Galetta SL, Ting TY, et al. Ross syndrome plus: beyond horner, Holmes-Adie, and harlequin. Neurology 2000; 55:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/39\">",
"      S&ouml;ylev MF, Saatci O, Kavukcu S, Ergin M. Adie's syndrome in childhood. Acta Paediatr Jpn 1997; 39:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/40\">",
"      Stromberg BV, Knibbe M. Anisocoria following reduction of bilateral orbital floor fractures. Ann Plast Surg 1988; 21:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/41\">",
"      Vetrugno R, Liguori R, Cevoli S, et al. Adie's tonic pupil as a manifestation of Sj&ouml;gren's syndrome. Ital J Neurol Sci 1997; 18:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/42\">",
"      Wabbels BK, Elflein H, Lorenz B, Kolling G. Bilateral tonic pupils with evidence of anti-hu antibodies as a paraneoplastic manifestation of small cell lung cancer. Ophthalmologica 2004; 218:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/43\">",
"      Weller M, Wilhelm H, Sommer N, et al. Tonic pupil, areflexia, and segmental anhidrosis: two additional cases of Ross syndrome and review of the literature. J Neurol 1992; 239:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/44\">",
"      Wirtz PW, de Keizer RJ, de Visser M, et al. Tonic pupils in Lambert-Eaton myasthenic syndrome. Muscle Nerve 2001; 24:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44117/abstract/45\">",
"      Wolfe GI, Galetta SL, Teener JW, et al. Site of autonomic dysfunction in a patient with Ross' syndrome and postganglionic Horner's syndrome. Neurology 1995; 45:2094.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5237 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44117=[""].join("\n");
var outline_f43_5_44117=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5237\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5237|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/29/6611\" title=\"figure 1\">",
"      Tonic pupil right eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5237|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/9/26770\" title=\"picture 1\">",
"      Bilateral tonic pupils",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5237|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/52/33612\" title=\"table 1\">",
"      Causes of tonic pupil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/49/31515\" title=\"table 2\">",
"      Infections and inflammatory causes of tonic pupil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/8/23691\" title=\"table 3\">",
"      Neuropathic causes of tonic pupil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/30/5611\" title=\"table 4\">",
"      Clinical features of tonic pupil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/32/2571\" title=\"table 5\">",
"      Causes of light near dissociation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/44/7883\" title=\"table 6\">",
"      Clinical features of Adies syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31206?source=related_link\">",
"      Approach to the patient with anisocoria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26312?source=related_link\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_5_44118="Transverse female pelvis";
var content_f43_5_44118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Transverse sections of the female pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 425px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse sections of the female pelvis.",
"    <br/>",
"    (A) Drawing of an anatomical section through the urinary bladder, uterus, and rectum.",
"    <br/>",
"    (B) Transverse ultrasound scan.",
"    <br/>",
"    (C) Drawing of an anatomical section through the urethra, vagina, and rectum.",
"    <br/>",
"    (D) Transverse magnetic resonance image (MRI).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Agur A. Essential Clinical Anatomy, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44118=[""].join("\n");
var outline_f43_5_44118=null;
var title_f43_5_44119="Emergency pericardiocentesis";
var content_f43_5_44119=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergency pericardiocentesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/5/44119/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/5/44119/contributors\">",
"     Alan C Heffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/5/44119/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/5/44119/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/5/44119/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/5/44119/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/5/44119/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/5/44119/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24600595\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial effusion and cardiac tamponade represent a spectrum of disease with wide variation in clinical presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. While all significant pericardial effusions are of clinical importance, emergency drainage is needed only for patients with hemodynamic compromise. Cardiac tamponade with hemodynamic collapse is an absolute indication for emergent pericardial drainage via pericardiocentesis or surgical pericardiotomy.",
"   </p>",
"   <p>",
"    The lethality of pericardial effusions has been recognized for centuries. Riolanus suggested sternal trephination to relieve pericardial pressure in 1653 and the Spanish physician Romero described intercostal surgical drainage in the early 19",
"    <sup>",
"     th",
"    </sup>",
"    century [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/3\">",
"     3",
"    </a>",
"    ]. The Viennese thoracic surgeon Franz Schuh performed the first successful blind pericardial aspiration in 1840 via a left parasternal approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/4\">",
"     4",
"    </a>",
"    ]. Marfan later described the subxiphoid technique in 1911 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/5\">",
"     5",
"    </a>",
"    ]. Despite significant complications and safety concerns, this remained the standard approach for blind pericardiocentesis through the late 20th century. Experience with echocardiography-directed pericardiocentesis paralleled technical advances in ultrasound during the 1970s, and has evolved as the procedure of choice due to its improved safety and efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Nonetheless, blind subcostal or parasternal pericardiocentesis remains a standard procedure for emergency pericardial drainage when ultrasound guidance is unavailable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The indications, contraindications, preparation, equipment, and techniques of emergency pericardiocentesis will be reviewed here. Cardiac tamponade and its related diseases and non-emergent pericardiocentesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27385?source=see_link\">",
"     \"Cardiac injury from blunt trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1050?source=see_link\">",
"     \"Pericardial disease associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25159?source=see_link\">",
"     \"Technique of pericardiocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600602\">",
"    <span class=\"h1\">",
"     ANATOMY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parietal pericardium is a fibrous sac that encloses the heart and the roots of the great vessels (",
"    <a class=\"graphic graphic_figure graphicRef67249 \" href=\"mobipreview.htm?39/32/40456\">",
"     figure 1",
"    </a>",
"    ). The cone-shaped sac rests on the diaphragm and fuses superiorly with the adventitia of the great vessels. The pericardium and heart lie between the pleural sacs. The pericardium is fixed within the thorax by attachments to the anterior diaphragm, the sternum, and the fourth and fifth left costal cartilages.",
"   </p>",
"   <p>",
"    In health, the pericardium envelops the heart loosely, but is rigid enough to provide stability within the thoracic cavity and to limit cardiac distention (pericardial constraint). The normal pericardial space contains &lt;50 mL of thin serous lubricating fluid, such that the pericardium closely delineates the heart and great vessels.",
"   </p>",
"   <p>",
"    Within the pericardium, the anterior sternocostal surface of the heart is dominated by low pressure right sided chambers while the left cardiac border and apex represent the left ventricle. The right coronary and left anterior descending coronary arteries course over the anterior surface of the heart where they are vulnerable to inadvertent puncture during pericardiocentesis.",
"   </p>",
"   <p>",
"    Several other important vessels course along the thoracic cage. Intercostal vessels course in their respective neurovascular bundles at the inferior rib margin. The left internal mammary artery courses parallel to the sternum 1 to 2 cm from the bony border before dividing into the superior epigastric and musculophrenic arteries at the sixth intercostal space.",
"   </p>",
"   <p>",
"    When performing the procedure, clinicians should be aware of the vital structures in proximity to the heart. These include the lungs, liver, and diaphragm. (",
"    <a class=\"graphic graphic_figure graphicRef80627 \" href=\"mobipreview.htm?18/39/19064\">",
"     figure 2",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    Critical cardiac compression can occur with the accumulation of fluid, pus, blood, clot, or gas in the pericardium. The cardiovascular consequences depend upon the amount and speed accumulation and the patient's physiologic reserve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/10\">",
"     10",
"    </a>",
"    ]. Cardiac tamponade represents the decompensated phase of cardiac compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600609\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no absolute contraindication to pericardiocentesis in an emergency. However, more definitive treatments should be considered if circumstances allow. Pericardiocentesis is a temporizing measure in acute traumatic hemopericardium and should not delay a more aggressive approach, such as emergency thoracotomy, when indicated. Such delays may increase mortality among trauma patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Management of nonhemorrhagic shock'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several relative contraindications to pericardiocentesis exist. Coagulopathy is an important consideration when deciding whether to perform any invasive procedure. Pericardiocentesis is relatively contraindicated when the effusion is associated with aortic dissection or myocardial rupture due to the potential risk of extending the dissection or rupture via rapid pericardial decompression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, such concerns are secondary if an alternative life-saving solution is not immediately available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600616\">",
"    <span class=\"h1\">",
"     MONITORING AND PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitor all critically ill patients continuously with both pulse oximetry and cardiac tracings. Before pericardiocentesis, provide airway and respiratory support as clinically indicated. Necessary interventions may range from supplemental oxygen to intubation and mechanical ventilation. Beware that a sudden decrease in preload, as occurs with rapid sequence intubation and positive-pressure ventilation, can cause acute decompensation, including cardiac arrest, in patients with tamponade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. It is prudent to obtain emergent surgical consultation in case surgical drainage is needed.",
"   </p>",
"   <p>",
"    Monitoring the electrocardiograph (ECG) tracing while advancing the pericardiocentesis needle, enables the clinician to detect needle contact with the epicardium, which helps prevent cardiac puncture. To do this, attach an alligator clip to the base of the pericardiocentesis needle and monitor it via a precordial (V) lead of an ECG machine set to continuous rhythm display. In this configuration, the pericardiocentesis needle acts as an exploring electrode.",
"   </p>",
"   <p>",
"    Contact of the needle with the epicardium is signaled by immediate ST and PR segment elevation with ventricular and atrial contact, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Should this occur, withdraw the needle immediately. ECG monitoring of the needle is not critical, and the practice may be omitted in an emergency, in the absence of essential equipment, or when there is concern for arrhythmias due to incomplete electrical grounding of the exploring electrode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/2,18,19\">",
"     2,18,19",
"    </a>",
"    ]. Ultrasound guidance obviates the need for ECG monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600623\">",
"    <span class=\"h1\">",
"     MATERIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 5 cm, 18 gauge spinal needle and large volume (60 to 80 mL) syringe are the minimum supplies needed for blind pericardiocentesis. In infants and small children, a 20 gauge spinal needle is recommended and in older children, a 4 cm (1.5 inch) 16 to 18 gauge over the needle catheter is used. If the need for pericardiocentesis is anticipated, all equipment necessary to optimize the procedure should be prepared. An equipment list is provided in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef72290 \" href=\"mobipreview.htm?17/36/17995\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Insertion of a pericardial drain is always preferred. If time allows, be sure to assemble these additional materials prior to performing the procedure. Preassembled pericardiocentesis sets are commercially available. Alternatively, a number of common six to eight French sterile catheters, including a pigtail catheter, cordis introducer sheath, or single or multi-lumen central venous catheter, may be substituted as a pericardial drain. Prepackaged central venous catheter sets provide most of the supplies needed for emergency pericardiocentesis. Unlike a spinal needle, the thin-walled 18 gauge needle included in pericardiocentesis and central venous access kits accommodate a standard J-tip guidewire for subsequent drain deployment.",
"   </p>",
"   <p>",
"    When using two-dimensional (2D) ultrasonography to guide pericardiocentesis, turn on the machine and allow it to warm up, then adjust it to the appropriate parameters. The procedure is typically performed with a 2 to 4 megahertz (MHz) probe. A standard curvilinear probe works well for subcostal views but a small footprint curved transducer improves intercostal imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600630\">",
"    <span class=\"h1\">",
"     TECHNIQUE OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600638\">",
"    <span class=\"h2\">",
"     General preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients experiencing hemodynamic collapse from cardiac tamponade are supine. Awake patients may experience profound dyspnea and orthopnea and require upright or semi-recumbent positioning for comfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Positioning at 30 to 45 degrees increases dependent pooling of fluid and brings the heart closer to the chest wall. Sedation is rarely required and is not recommended in stuporous patients due to the risk of hemodynamic decompensation. If sedation is used in awake patients without obvious hemodynamic compromise, short-acting medications (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ) are preferred.",
"   </p>",
"   <p>",
"    The optimal approach to pericardial drainage depends upon patient habitus, the distribution of pericardial fluid, and the availability of ultrasound. Ultrasound, or echocardiography, is the most common means of confirming a pericardial effusion and enables safer and more reliable percutaneous drainage compared with a blind approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/22\">",
"     22",
"    </a>",
"    ]. The ultrasound guided approach is effective in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/23\">",
"     23",
"    </a>",
"    ]. However, blind pericardial drainage may be necessary for patients with suspected deterioration from cardiac tamponade and when ultrasound is unavailable. A high quality video demonstrating emergency pericardiocentesis is available using the following reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the difficulties encountered in emergency circumstances, every effort should be made to use aseptic technique when performing emergency pericardiocentesis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prepare the skin by applying a chlorhexidine-based solution to the chest and upper abdomen and drape the region to maintain sterility during hardware manipulation. Don a sterile gown, gloves, mask, and hat.",
"     </li>",
"     <li>",
"      Anesthetize the puncture site and needle track in alert patients via infiltration of local anesthetic (eg, 1 to 2 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ). The pericardium is very sensitive and should also be anesthetized.",
"     </li>",
"     <li>",
"      Perform pericardiocentesis at the selected site. (See",
"      <a class=\"local\" href=\"#H24600645\">",
"       'Selecting the approach for pericardiocentesis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Simple needle aspiration provides immediate hemodynamic benefit, but secondary placement of a pericardial drain is recommended to ensure continuous access. The Seldinger guidewire technique is preferred. Access to the pericardial space is gained using a 5 cm, 18 gauge, thin-walled introducer needle or sheathed catheter over needle assembly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600645\">",
"    <span class=\"h2\">",
"     Selecting the approach for pericardiocentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial fluid is not always circumferential or equally distributed within the pericardial sac. Loculation occurs in up to one-third of nontraumatic effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Also remember that the critical volume sufficient to cause tamponade is much smaller when pericardial fluid has accumulated rapidly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound determination of the ideal drainage site and needle trajectory has supplanted estimation based upon palpation and percussion. Systematic ultrasound assessment is performed using several windows (subcostal, parasternal, and apical). Observational studies of fluid distribution with pericardial effusions suggest that several access sites in the left chest are superior to the traditional subxiphoid approach, and uncontrolled echocardiography-directed studies confirm successful aspiration from these sites in patients selected using real-time ultrasound guidance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/8,22,27-29\">",
"     8,22,27-29",
"    </a>",
"    ]. Among potential chest sites, the left parasternal, and apical approaches are most commonly used (",
"    <a class=\"graphic graphic_figure graphicRef81176 \" href=\"mobipreview.htm?15/33/15893\">",
"     figure 3",
"    </a>",
"    ). The parasternal and apical approaches have not been studied in infants or children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600652\">",
"    <span class=\"h3\">",
"     Subcostal (subxiphoid)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extrapleural subcostal pericardiocentesis approach is performed as follows (",
"    <a class=\"graphic graphic_figure graphicRef81442 \" href=\"mobipreview.htm?22/40/23169\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/2,9,19,30,31\">",
"     2,9,19,30,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Introduce the needle substernally 1 cm inferior to the left xiphocostal angle. Once beneath the cartilage cage, lower the needle so it approximates a 15 to 30 degree angle with the abdominal wall.",
"     </li>",
"     <li>",
"      Aim the needle toward the left shoulder and advance it slowly while continuously aspirating. If no fluid is aspirated, the needle should be withdrawn promptly and redirected. In the absence of ultrasound guidance, withdraw the needle to the skin and redirect it along a deeper posterior trajectory. The required depth of insertion is affected by the patient&rsquo;s anatomy. In most cases, a 5 cm needle is adequate, but longer needles (up to 10 cm) may be needed for obese patients. In infants and small children, 4 cm (1.5 inch) needles are sufficient.",
"     </li>",
"     <li>",
"      If no fluid is aspirated on the second attempt, withdraw the needle to the skin and redirect it 15 degrees to the patient&rsquo;s right of the last dry needle path. Perform systematic redirected aspirations by working from the patient's left to right until the needle is aimed toward the right shoulder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ultrasound guidance generally enables the clinician to avoid inserting the needle into other organs. However, interposition of the left liver lobe is often recognized on subcostal imaging and the lobe may be traversed intentionally during pericardiocentesis, if an alternative site is not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600659\">",
"    <span class=\"h3\">",
"     Parasternal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left sternal border is the landmark for a parasternal approach (",
"    <a class=\"graphic graphic_figure graphicRef54637 \" href=\"mobipreview.htm?26/5/26705\">",
"     figure 5",
"    </a>",
"    ). Left parasternal access is most frequently used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insert the needle perpendicular to the skin and over the cephalad border of the fifth or sixth rib immediately adjacent to the sternal margin. The cardiac notch of the left lung exposes the pericardium at this site.",
"     </li>",
"     <li>",
"      Avoid puncturing more laterally (greater than 1 cm) to prevent injury to the internal mammary artery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An analogous right parasternal approach is occasionally used when ultrasound predicts superior access from this site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600666\">",
"    <span class=\"h3\">",
"     Apical",
"    </span>",
"    &nbsp;&mdash;&nbsp;The apical pericardiocentesis approach reduces the risk of cardiac complications by taking advantage of the proximity to the thick walled left ventricle and the small apical coronary vessels (",
"    <a class=\"graphic graphic_figure graphicRef69561 \" href=\"mobipreview.htm?32/54/33633\">",
"     figure 6",
"    </a>",
"    ). However, proximity to the left pleural space increases the risk for pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The apical insertion site is at least 5 centimeters lateral to the parasternal approach within the fifth, sixth, or seventh intercostal space. Advance the needle over the cephalad border of the rib and towards the patient&rsquo;s right shoulder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600673\">",
"    <span class=\"h2\">",
"     Ultrasound-guided pericardiocentesis technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the high rates of procedure related complications associated with blind aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/4,7,33-35\">",
"     4,7,33-35",
"    </a>",
"    ], multiple observational studies of ultrasound-guided pericardiocentesis report improved safety, clinician satisfaction, and success (greater than 97 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/27,28,36,37\">",
"     27,28,36,37",
"    </a>",
"    ]. Ultrasound remains the principal diagnostic test to confirm critical pericardial effusion and should always be used to guide aspiration when available (",
"    <a class=\"graphic graphic_figure graphicRef54637 \" href=\"mobipreview.htm?26/5/26705\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69561 \" href=\"mobipreview.htm?32/54/33633\">",
"     figure 6",
"    </a>",
"    ). A high quality video demonstrating emergency pericardiocentesis is available using the following reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perform ultrasound-directed pericardiocentesis as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prepare the patient and assemble the necessary equipment. (See",
"      <a class=\"local\" href=\"#H24600638\">",
"       'General preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Using ultrasound, determine the presence and distribution of pericardial fluid. Systematically examine the heart and look for effusions at each imaging window (subcostal, parasternal, apical, and any additional views).",
"     </li>",
"     <li>",
"      Select the best entry site. This site contains the largest pericardial fluid accumulation that is closest to the chest wall and can be entered without puncturing any adjacent vital organs.",
"     </li>",
"     <li>",
"      Select a target fluid layer (distance from pericardium to epicardium) of at least 1 cm to avoid cardiac puncture. Ultrasound does not pass through air so the lung is avoided if the needle trajectory mirrors the approach delineated by ultrasound.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of three techniques may be employed for ultrasound-guided pericardiocentesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Static",
"      </strong>",
"      imaging uses still images for procedure planning, but does not provide real-time ultrasound imaging during the procedure.",
"     </li>",
"     <li>",
"      <strong>",
"       Remote",
"      </strong>",
"      guidance uses ultrasound to view the heart and effusion during the procedure but often gives no direct observation of needle penetration.",
"     </li>",
"     <li>",
"      <strong>",
"       Dynamic",
"      </strong>",
"      guidance uses real time ultrasound imagery to view and guide the needle during the approach and pericardial puncture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no data to support any one technique and the clinician should determine the best approach based on experience and available resources. If static imaging is used, outline the skin puncture site and trajectory with two skin marks. The needle trajectory mirrors the transducer angle used during ultrasonography of the target effusion. Note this angle carefully while imaging the effusion. Measure the distance from the skin to the pericardium overlying the target effusion; the distance is typically 2 to 4 cm. Monitor fluid removal from a remote transducer position.",
"   </p>",
"   <p>",
"    For the dynamic approach, orient and insert the needle parallel to the localizing ultrasound beam. Real-time ultrasound visualization of needle passage is optimal, but may be difficult with a low frequency transducer. Use of a needle guide affixed to the ultrasound probe helps align the needle for dynamic ultrasound guided insertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/29,38\">",
"     29,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800834\">",
"    <span class=\"h2\">",
"     Pericardiocentesis technique without ultrasound guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;When ultrasound is not available, perform emergent pericardiocentesis as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prepare the patient and necessary equipment as above. (See",
"      <a class=\"local\" href=\"#H24600638\">",
"       'General preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Slowly advance the pericardiocentesis needle in the predetermined trajectory with continuous aspiration of the attached syringe. Move the needle along a single in-and-out vector only; side to side movement of the needle tip can lacerate tissue.",
"     </li>",
"     <li>",
"      Increased resistance to the needle, followed by a distinct give or pop, suggests penetration of the pericardium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/10,19\">",
"       10,19",
"      </a>",
"      ]. Stop advancing the needle once fluid is freely aspirated.",
"     </li>",
"     <li>",
"      Attach a surgical clamp to the needle shaft at the skin surface to brace the needle and prevent inadvertent movement during the ensuing steps. A ticking sensation signifies needle contact with the epicardium. If this occurs, withdraw the needle slightly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If a catheter-over-needle assembly is used for initial access, insert the needle an additional 2 mm after initial fluid aspiration, and advance the catheter over the core needle into the pericardial space [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If drain insertion is intended, aspirate several milliliters to confirm free flowing pericardial fluid, but do not withdraw a large amount of fluid in an attempt to drain the pericardium completely as this will hinder subsequent guidewire deployment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3895995\">",
"    <span class=\"h2\">",
"     Intrapericardial needle confirmation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration of fluid does not always confirm pericardial drainage, as pleural and peritoneal collections may be traversed during pericardiocentesis. Similarly, withdrawal of bloody fluid may represent hemopericardium or accidental cardiac puncture, which can be difficult to discriminate. Hemodynamic improvement following aspiration of bloody fluid is more consistent with pericardial aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/40\">",
"     40",
"    </a>",
"    ]. Monitoring fluid removal from a remote transducer position can be helpful.",
"   </p>",
"   <p>",
"    Ultrasound localization of the needle tip is difficult. Bubble contrast injection through the exploring needle makes detection of the tip easier and helps to confirm needle position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/9,41\">",
"     9,41",
"    </a>",
"    ]. Prepare agitated saline bubble contrast by rapidly mixing 9 mL of saline with 1 mL of air between two connected syringes immediately before injection. Layering of contrast outside the heart confirms pericardial localization. Rapid contrast washout or intracardiac swirling varies with the patient's cardiac output, but both signify myocardial perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600687\">",
"    <span class=\"h2\">",
"     Drain placement",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exchange the needle (or catheter, if a catheter-over-needle assembly was used) for a more robust drain via the Seldinger technique. Following confirmatory aspiration of pericardial fluid, pass a flexible tipped guidewire through the needle into the pericardial sac. Remove the needle while securing the guidewire in place to maintain pericardial access.",
"     </li>",
"     <li>",
"      Make a small stab skin incision at the entry site. Dilate the chest wall passage and pericardium with a tissue dilator prior to drain insertion.",
"     </li>",
"     <li>",
"      Advance the drain into position over the indwelling guidewire, and then withdraw the guidewire. Confirm proper drain placement by aspirating pericardial fluid.",
"     </li>",
"     <li>",
"      Secure the drain in place on the chest wall with sutures and place a dry sterile dressing over the site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600702\">",
"    <span class=\"h2\">",
"     Catheter drainage and care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume of pericardial fluid required to relieve tamponade varies significantly among patients depending upon their position on the pericardial pressure-volume curve. Once the catheter is in place, aspirate pericardial fluid rapidly using a large syringe (60 to 80 mL) until cardiopulmonary compromise is relieved. Place a three-way stopcock between the catheter and aspirating syringe to aid in rapid serial aspirations while maintaining sterility. Limit acute drainage of large effusions to less than 1 L [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/9,43\">",
"     9,43",
"    </a>",
"    ]. Keep the catheter connected to a sterile closed drainage system after initial aspiration. Do not use continuous negative pressure systems or vacuum containers.",
"   </p>",
"   <p>",
"    Anticipate pericardial reaccumulation after initial decompression. Avoid continuous drainage because of the high rate of catheter occlusion; intermittent drainage optimizes drain patency. Flush the indwelling catheter with 5 mL of sterile or heparinized saline between aspirations, performed every four to six hours or as clinically indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/8\">",
"     8",
"    </a>",
"    ]. Inadequate initial drainage or reaccumulation despite a functioning drain indicates the need for immediate surgical drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600709\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large observational studies of echocardiography-guided pericardiocentesis report a major complication rate of &lt;2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/9,27,28,44,45\">",
"     9,27,28,44,45",
"    </a>",
"    ]. However, delayed clinical decompensation following attempted and successful pericardiocentesis may also reflect procedural complications.",
"   </p>",
"   <p>",
"    The most serious and immediate mechanical complications of pericardiocentesis are myocardial puncture or laceration, vascular injury (coronary, intercostal, internal mammary, or intraabdominal), pneumothorax, air embolism, and arrhythmia (ventricular and supraventricular). Myocardial and coronary puncture may be initially silent and present with delayed hemopericardium that is poorly responsive to needle or catheter aspiration.",
"   </p>",
"   <p>",
"    Purposeful or inadvertent transperitoneal needle passage can traverse intraabdominal organs. The liver is most commonly involved, but is associated with low risk of significant hemorrhage. Perforation of a hollow viscus is theoretically possible, but rarely reported.",
"   </p>",
"   <p>",
"    Vasovagal response to pericardial decompression occurs in up to 25 percent of patients and may be severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. Successful pericardial decompression may also induce acute left or right ventricular dysfunction unrelated to anatomic injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/43,46-48\">",
"     43,46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lastly, pericardiocentesis may fail to relieve tamponade. Loculated effusion and acute hemopericardium are factors associated with unsuccessful catheter drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44119/abstract/25,27,28,36\">",
"     25,27,28,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1617332\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pericardial effusion and cardiac tamponade represent a spectrum of disease with wide variation in clinical presentation. The cardiovascular consequences of pericardial effusion depend upon the amount of fluid, the speed with which it accumulates, and the patient's physiologic reserve. Emergency drainage is needed only for patients with hemodynamic compromise. Cardiac tamponade with hemodynamic collapse is an absolute indication for emergent pericardial drainage via pericardiocentesis or surgical pericardiotomy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H24600602\">",
"       'Anatomy and physiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24600609\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring of patients needing emergency pericardiocentesis is performed with pulse oximetry and cardiac tracings. Monitoring the electrocardiogram tracing while advancing the pericardiocentesis needle can help prevent cardiac puncture, but it is not essential, especially when ultrasound guidance is used. Before pericardiocentesis, provide airway and respiratory support as clinically indicated. Beware that a sudden decrease in preload, as occurs with tracheal intubation and positive-pressure ventilation, can cause acute decompensation, including cardiac arrest, in patients with tamponade. (See",
"      <a class=\"local\" href=\"#H24600616\">",
"       'Monitoring and preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The materials needed to perform emergency pericardiocentesis are described in the text and listed in the attached table (",
"      <a class=\"graphic graphic_table graphicRef72290 \" href=\"mobipreview.htm?17/36/17995\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24600623\">",
"       'Materials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal approach to pericardial drainage depends upon patient habitus, the distribution of pericardial fluid, and the availability of ultrasound. Pericardial fluid is not always circumferential or equally distributed within the pericardial sac. Loculation occurs in up to one-third of nontraumatic effusions. Ultrasound is the most common means of confirming a pericardial effusion and enables safer and more reliable percutaneous drainage compared with a blind approach. However, blind pericardial drainage may be necessary for patients with suspected deterioration from cardiac tamponade and when ultrasound is unavailable. (See",
"      <a class=\"local\" href=\"#H24600638\">",
"       'General preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Observational studies of pericardial collection distribution suggest that several chest access sites are frequently superior to the traditional subxiphoid approach. Ultrasound often demonstrates the left parasternal and apical sites as optimal approaches. (See",
"      <a class=\"local\" href=\"#H24600645\">",
"       'Selecting the approach for pericardiocentesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The performance of both ultrasound-guided and blind emergency pericardiocentesis is described in the text. (See",
"      <a class=\"local\" href=\"#H24600673\">",
"       'Ultrasound-guided pericardiocentesis technique'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H800834\">",
"       'Pericardiocentesis technique without ultrasound guidance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/1\">",
"      Reddy PS, Curtiss EI, Uretsky BF. Spectrum of hemodynamic changes in cardiac tamponade. Am J Cardiol 1990; 66:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/2\">",
"      Spodick DH. Acute cardiac tamponade. N Engl J Med 2003; 349:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/3\">",
"      Loukas M, Walters A, Boon JM, et al. Pericardiocentesis: a clinical anatomy review. Clin Anat 2012; 25:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/4\">",
"      Wong B, Murphy J, Chang CJ, et al. The risk of pericardiocentesis. Am J Cardiol 1979; 44:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/5\">",
"      Kilpatrick ZM, Chapman CB. On pericardiocentesis. Am J Cardiol 1965; 16:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/6\">",
"      Goldberg BB, Pollack HM. Ultrasonically guided pericardiocentesis. Am J Cardiol 1973; 31:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/7\">",
"      Callahan JA, Seward JB. Pericardiocentesis Guided by Two-Dimensional Echocardiography. Echocardiography 1997; 14:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/8\">",
"      Tsang TS, Freeman WK, Sinak LJ, Seward JB. Echocardiographically guided pericardiocentesis: evolution and state-of-the-art technique. Mayo Clin Proc 1998; 73:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/9\">",
"      Maisch B, Seferovi PM, Risti AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004; 25:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/10\">",
"      Spodick DH. Pathophysiology of cardiac tamponade. Chest 1998; 113:1372.",
"     </a>",
"    </li>",
"    <li>",
"     Harper, Richard, J.. Pericardiocentesis. In: Clinical Procedures in Emergency Medicine, 5, Roberts, JR, Hedges, JR (Eds), Saunders Elsevier, Philadelphia 2010. p.287.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/12\">",
"      Isselbacher EM, Cigarroa JE, Eagle KA. Cardiac tamponade complicating proximal aortic dissection. Is pericardiocentesis harmful? Circulation 1994; 90:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/13\">",
"      Silvestry FE, Kerber RE, Brook MM, et al. Echocardiography-guided interventions. J Am Soc Echocardiogr 2009; 22:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/14\">",
"      Mackersie RC. Pitfalls in the evaluation and resuscitation of the trauma patient. Emerg Med Clin North Am 2010; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/15\">",
"      Ho AM, Graham CA, Ng CS, et al. Timing of tracheal intubation in traumatic cardiac tamponade: a word of caution. Resuscitation 2009; 80:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/16\">",
"      BISHOP LH Jr, ESTES EH Jr, MCINTOSH HD. The electrocardiogram as a safeguard in pericardiocentesis. J Am Med Assoc 1956; 162:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/17\">",
"      Kerber RE, Ridges JD, Harrison DC. Electrocardiographic indications of atrial puncture during pericardiocentesis. N Engl J Med 1970; 282:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/18\">",
"      Sobol SM, Thomas HM Jr, Evans RW. Myocardial laceration not demonstrated by continuous electrocardiographic monitoring occurring during pericardiocentesis. N Engl J Med 1975; 292:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/19\">",
"      Park SC, Pahl E, Ettedgui JA, et al. Experience with a newly developed pericardiocentesis set. Am J Cardiol 1990; 66:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/20\">",
"      Porter JM, Ivatury RR. Unwillingness to lie supine? a sign of pericardial tamponade. Am Surg 1997; 63:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/21\">",
"      Roy CL, Minor MA, Brookhart MA, Choudhry NK. Does this patient with a pericardial effusion have cardiac tamponade? JAMA 2007; 297:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/22\">",
"      Callahan JA, Seward JB, Tajik AJ. Cardiac tamponade: pericardiocentesis directed by two-dimensional echocardiography. Mayo Clin Proc 1985; 60:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/23\">",
"      Guven H, Bakiler AR, Ulger Z, et al. Evaluation of children with a large pericardial effusion and cardiac tamponade. Acta Cardiol 2007; 62:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/24\">",
"      Fitch MT, Nicks BA, Pariyadath M, et al. Videos in clinical medicine. Emergency pericardiocentesis. N Engl J Med 2012; 366:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/25\">",
"      Cooper JP, Oliver RM, Currie P, et al. How do the clinical findings in patients with pericardial effusions influence the success of aspiration? Br Heart J 1995; 73:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/26\">",
"      Tsang TS, Barnes ME, Hayes SN, et al. Clinical and echocardiographic characteristics of significant pericardial effusions following cardiothoracic surgery and outcomes of echo-guided pericardiocentesis for management: Mayo Clinic experience, 1979-1998. Chest 1999; 116:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/27\">",
"      Tsang TS, Enriquez-Sarano M, Freeman WK, et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc 2002; 77:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/28\">",
"      Cho BC, Kang SM, Kim DH, et al. Clinical and echocardiographic characteristics of pericardial effusion in patients who underwent echocardiographically guided pericardiocentesis: Yonsei Cardiovascular Center experience, 1993-2003. Yonsei Med J 2004; 45:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/29\">",
"      Hanaki Y, Kamiya H, Todoroki H, et al. New two-dimensional, echocardiographically directed pericardiocentesis in cardiac tamponade. Crit Care Med 1990; 18:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/30\">",
"      Ellis H. The clinical anatomy of pericardiocentesis. Br J Hosp Med (Lond) 2010; 71:M100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/31\">",
"      John RM, Treasure T. How to aspirate the pericardium. Br J Hosp Med 1990; 43:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/32\">",
"      Brown CG, Gurley HT, Hutchins GM, et al. Injuries associated with percutaneous placement of transthoracic pacemakers. Ann Emerg Med 1985; 14:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/33\">",
"      Krikorian JG, Hancock EW. Pericardiocentesis. Am J Med 1978; 65:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/34\">",
"      Guberman BA, Fowler NO, Engel PJ, et al. Cardiac tamponade in medical patients. Circulation 1981; 64:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/35\">",
"      Kwasnik EM, Koster K, Lazarus JM, et al. Conservative management of uremic pericardial effusions. J Thorac Cardiovasc Surg 1978; 76:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/36\">",
"      Lindenberger M, Kjellberg M, Karlsson E, Wranne B. Pericardiocentesis guided by 2-D echocardiography: the method of choice for treatment of pericardial effusion. J Intern Med 2003; 253:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/37\">",
"      Kil UH, Jung HO, Koh YS, et al. Prognosis of large, symptomatic pericardial effusion treated by echo-guided percutaneous pericardiocentesis. Clin Cardiol 2008; 31:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/38\">",
"      Maggiolini S, Bozzano A, Russo P, et al. Echocardiography-guided pericardiocentesis with probe-mounted needle: report of 53 cases. J Am Soc Echocardiogr 2001; 14:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/39\">",
"      Spodick DH. The technique of pericardiocentesis. When to perform it and how to minimize complications. J Crit Illn 1995; 10:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/40\">",
"      Iskandrian AS. Practical considerations in pericardiocentesis. Cathet Cardiovasc Diagn 1989; 16:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/41\">",
"      Vayre F, Lardoux H, Pezzano M, et al. Subxiphoid pericardiocentesis guided by contrast two-dimensional echocardiography in cardiac tamponade: experience of 110 consecutive patients. Eur J Echocardiogr 2000; 1:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/42\">",
"      Ainsworth CD, Salehian O. Echo-guided pericardiocentesis: let the bubbles show the way. Circulation 2011; 123:e210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/43\">",
"      Armstrong WF, Feigenbaum H, Dillon JC. Acute right ventricular dilation and echocardiographic volume overload following pericardiocentesis for relief of cardiac tamponade. Am Heart J 1984; 107:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/44\">",
"      Bastian A, Meissner A, Lins M, et al. Pericardiocentesis: differential aspects of a common procedure. Intensive Care Med 2000; 26:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/45\">",
"      Tsang TS, Freeman WK, Barnes ME, et al. Rescue echocardiographically guided pericardiocentesis for cardiac perforation complicating catheter-based procedures. The Mayo Clinic experience. J Am Coll Cardiol 1998; 32:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/46\">",
"      Glasser F, Fein AM, Feinsilver SH, et al. Non-cardiogenic pulmonary edema after pericardial drainage for cardiac tamponade. Chest 1988; 94:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/47\">",
"      Wolfe MW, Edelman ER. Transient systolic dysfunction after relief of cardiac tamponade. Ann Intern Med 1993; 119:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44119/abstract/48\">",
"      Vandyke WH Jr, Cure J, Chakko CS, Gheorghiade M. Pulmonary edema after pericardiocentesis for cardiac tamponade. N Engl J Med 1983; 309:595.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13823 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44119=[""].join("\n");
var outline_f43_5_44119=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1617332\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24600595\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24600602\">",
"      ANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24600609\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24600616\">",
"      MONITORING AND PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24600623\">",
"      MATERIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24600630\">",
"      TECHNIQUE OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24600638\">",
"      General preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24600645\">",
"      Selecting the approach for pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24600652\">",
"      - Subcostal (subxiphoid)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24600659\">",
"      - Parasternal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24600666\">",
"      - Apical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24600673\">",
"      Ultrasound-guided pericardiocentesis technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H800834\">",
"      Pericardiocentesis technique without ultrasound guidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3895995\">",
"      Intrapericardial needle confirmation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24600687\">",
"      Drain placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24600702\">",
"      Catheter drainage and care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24600709\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1617332\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13823\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13823|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/32/40456\" title=\"figure 1\">",
"      Sternum pericardium and related anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/39/19064\" title=\"figure 2\">",
"      Rib and chest anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/33/15893\" title=\"figure 3\">",
"      Pericardiocentesis sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/40/23169\" title=\"figure 4\">",
"      Emergency pericardiocentesis subxiphoid approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/5/26705\" title=\"figure 5\">",
"      Emergency pericardiocentesis parasternal approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/54/33633\" title=\"figure 6\">",
"      Emergency pericardiocentesis apical approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13823|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/36/17995\" title=\"table 1\">",
"      Emergency pericardiocentesis equipment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27385?source=related_link\">",
"      Cardiac injury from blunt trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1050?source=related_link\">",
"      Pericardial disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25159?source=related_link\">",
"      Technique of pericardiocentesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_5_44120="Betamethasone: Drug information";
var content_f43_5_44120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Betamethasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/7/7287?source=see_link\">",
"    see \"Betamethasone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/7/28791?source=see_link\">",
"    see \"Betamethasone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Celestone&reg;;",
"     </li>",
"     <li>",
"      Celestone&reg; Soluspan&reg;;",
"     </li>",
"     <li>",
"      Diprolene&reg;;",
"     </li>",
"     <li>",
"      Diprolene&reg; AF;",
"     </li>",
"     <li>",
"      Luxiq&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Betaderm;",
"     </li>",
"     <li>",
"      Betaject&trade;;",
"     </li>",
"     <li>",
"      Betnesol&reg;;",
"     </li>",
"     <li>",
"      Betnovate&reg;;",
"     </li>",
"     <li>",
"      Celestone&reg; Soluspan&reg;;",
"     </li>",
"     <li>",
"      Diprolene&reg;;",
"     </li>",
"     <li>",
"      Diprolene&reg; Glycol;",
"     </li>",
"     <li>",
"      Diprosone&reg;;",
"     </li>",
"     <li>",
"      Ectosone;",
"     </li>",
"     <li>",
"      Prevex&reg; B;",
"     </li>",
"     <li>",
"      ratio-Ectosone;",
"     </li>",
"     <li>",
"      Ratio-Topilene;",
"     </li>",
"     <li>",
"      ratio-Topilene;",
"     </li>",
"     <li>",
"      Ratio-Topisone;",
"     </li>",
"     <li>",
"      ratio-Topisone;",
"     </li>",
"     <li>",
"      Rivasone;",
"     </li>",
"     <li>",
"      Rolene;",
"     </li>",
"     <li>",
"      Rosone;",
"     </li>",
"     <li>",
"      Taro-Sone;",
"     </li>",
"     <li>",
"      Valisone&reg; Scalp Lotion",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F140691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Systemic;",
"     </li>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F140649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Base dosage on severity of disease and patient response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inflammatory conditions:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     2.4-4.8 mg/day in 2-4 doses; range: 0.6-7.2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"     Betamethasone sodium phosphate and betamethasone acetate: 0.6-9 mg/day (generally,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of oral dose) divided every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psoriasis (scalp):",
"     </b>",
"     Topical (foam): Apply to the scalp twice daily, once in the morning and once at night.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis/osteoarthritis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intrabursal, intra-articular, intradermal:",
"     </i>",
"     0.25-2 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intralesional:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Very large joints: 1-2 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Large joints: 1 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Medium joints: 0.5-1 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Small joints: 0.25-0.5 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Steroid-responsive dermatoses:",
"     </b>",
"     Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel, augmented formulation: Apply once or twice daily; rub in gently.",
"     <b>",
"      Note:",
"     </b>",
"     Do not exceed 2 weeks of treatment or 50 g/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotion: Apply a few drops twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Augmented formulation: Apply a few drops once or twice daily; rub in gently.",
"     <b>",
"      Note:",
"     </b>",
"     Do not exceed 2 weeks of treatment or 50 mL/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cream/ointment: Apply once or twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Augmented formulation: Apply once or twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Do not exceed 2 weeks of treatment or 45 g/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antenatal fetal maturation (unlabeled use):",
"     </b>",
"     <i>",
"      I.M.:",
"     </i>",
"     12 mg every 24 hours for a total of 2 doses apart (ACOG, 2011).",
"     <b>",
"      Note:",
"     </b>",
"     Recommended for pregnant women with premature labor (24-34 weeks gestation) who are expected to deliver within 7 days.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F140670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/7/28791?source=see_link\">",
"      see \"Betamethasone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Base dosage on severity of disease and patient response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inflammatory conditions:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Use lowest dose listed as initial dose for adrenocortical insufficiency (physiologic replacement).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &le;12 years: 0.0175-0.125 mg base/kg/day divided every 6-12 hours",
"     <b>",
"      or",
"     </b>",
"     0.5-7.5 mg base/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;13 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &le;12 years: 0.0175-0.25 mg/kg/day divided every 6-8 hours",
"     <b>",
"      or",
"     </b>",
"     0.5-7.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;13 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Topical:",
"     </i>",
"     Children &ge;13 years (use in children &le;12 years is not recommended): Use minimal amount for shortest period of time to avoid HPA axis suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Steroid-responsive dermatoses:",
"     </b>",
"     Topical: Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F140650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use the lowest effective dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F140651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjustments may be necessary in patients with liver failure because betamethasone is extensively metabolized in the liver",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical, as valerate: 0.12% (50 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Luxiq&reg;: 0.12% (50 g, 100 g) [contains ethanol 60.4%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as dipropionate [strength expressed as base]: 0.05% (15 g, 45 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as dipropionate [strength expressed as base, augmented]: 0.05% (15 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diprolene&reg; AF: 0.05% (15 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as valerate [strength expressed as base]: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as dipropionate [strength expressed as base, augmented]: 0.05% (15 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension: Betamethasone sodium phosphate 3 mg and betamethasone acetate 3 mg per 1 mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Celestone&reg; Soluspan&reg;: Betamethasone sodium phosphate 3 mg and betamethasone acetate 3 mg per 1 mL (5 mL) [contains benzalkonium chloride, edetate disodium; total of 6 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as dipropionate [strength expressed as base]: 0.05% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as dipropionate [strength expressed as base, augmented]: 0.05% (30 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diprolene&reg;: 0.05% (30 mL, 60 mL) [contains isopropyl alcohol 30%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as valerate [strength expressed as base]: 0.1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as dipropionate [strength expressed as base]: 0.05% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as dipropionate [strength expressed as base, augmented]: 0.05% (15 g, 45 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diprolene&reg;: 0.05% (15 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as valerate [strength expressed as base]: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Celestone&reg;: 0.6 mg/5 mL (118 mL) [contains ethanol &lt;1%, propylene glycol, sodium benzoate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F140625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Not for alternate day therapy; once daily doses should be given in the morning. May be administered with food to decrease GI distress.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Do",
"     <b>",
"      not",
"     </b>",
"     give injectable sodium phosphate/acetate suspension I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Apply topical sparingly to areas. Not for use on broken skin or in areas of infection. Do not apply to wet skin unless directed; do not cover with occlusive dressing. Do not apply very high potency agents to face, groin, axillae, or diaper area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Foam: Invert can and dispense a small amount onto a saucer or other cool surface. Do not dispense directly into hands. Pick up small amounts of foam and gently massage into affected areas until foam disappears. Repeat until entire affected scalp area is treated.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F140698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F140624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inflammatory dermatoses such as seborrheic or atopic dermatitis, neurodermatitis, anogenital pruritus, psoriasis, inflammatory phase of xerosis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6495893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Accelerate fetal lung maturation in patients with preterm labor",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F140700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Luxiq&reg; may be confused with Lasix&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Beta-Val [U.S.] may be confused with Betanol brand name for metipranolol [Monaco]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F140689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Systemic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Congestive heart failure, edema, hyper-/hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, insomnia, intracranial pressure increased, lightheadedness, nervousness, pseudotumor cerebri, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Ecchymoses, facial erythema, fragile skin, hirsutism, hyper-/hypopigmentation, perioral dermatitis (oral), petechiae, striae, wound healing impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, Cushing's syndrome, diabetes mellitus, growth suppression, hyperglycemia, hypokalemia, menstrual irregularities, pituitary-adrenal axis suppression, protein catabolism, sodium retention, water retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, appetite increased, hiccups, indigestion, peptic ulcer, pancreatitis, ulcerative esophagitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions (intra-articular use), sterile abscess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, muscle atrophy, fractures, muscle weakness, myopathy, osteoporosis, necrosis (femoral and humeral heads)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, glaucoma, intraocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reaction, diaphoresis, hypersensitivity, secondary infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Topical:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acneiform eruptions, allergic dermatitis, burning, dry skin, erythema, folliculitis, hypertrichosis, irritation, miliaria, pruritus, skin atrophy, striae, vesiculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine and metabolic effects have occasionally been reported with topical use.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F140628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to betamethasone, other corticosteroids, or any component of the formulation; systemic fungal infections; I.M. administration contraindicated in idiopathic thrombocytopenia purpura",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F140612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections. In stressful situations, HPA axis-suppressed patients should receive adequate supplementation with natural glucocorticoids (hydrocortisone or cortisone) rather than betamethasone (due to lack of mineralocorticoid activity).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: Discontinue if skin irritation or contact dermatitis should occur; do not use in patients with decreased skin circulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with HF; long-term use has been associated with fluid retention and hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head injury: Increased mortality was observed in patients receiving high-dose I.V. methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarction (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Topical use in patients &le;12 years of age is not recommended. Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical: Do not use occlusive dressings on weeping or exudative lesions and general caution with occlusive dressings should be observed; adverse effects may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Very high potency topical products: Not for treatment of rosacea, perioral dermatitis; not for use on face, groin, or axillae; not for use in a diapered area. Avoid concurrent use of other corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F140684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F140640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Betamethasone interferes with calcium absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid cat's claw, echinacea (have immunostimulant properties).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F140618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F140631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Betamethasone crosses the placenta; approximately 25% is metabolized by placental enzymes to an inactive metabolite. Due to its positive effect on stimulating fetal lung maturation, a single course of the injection is often used in patients with premature labor (24-34 weeks gestation) who are expected to deliver within 7 days. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Women exposed to betamethasone during pregnancy for the treatment of an autoimmune disease may contact the OTIS Autoimmune Diseases Study at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F140654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F140632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroids are excreted in human milk. The onset of milk secretion after birth may be delayed and the volume of milk produced may be decreased by antenatal betamethasone therapy; this affect was seen when delivery occurred 3-9 days after the betamethasone dose in women between 28 and 34 weeks gestation. Antenatal betamethasone therapy did not affect milk production when birth occurred &lt;3 days or &gt;10 days of treatment. It is not known if systemic absorption following topical administration results in detectable quantities in human milk. Use with caution while breast-feeding; do not apply to nipples.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F140633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food to decrease GI distress.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F140630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Betamethasone Dipropionate Aug External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $38.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Betamethasone Dipropionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $41.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Betamethasone Valerate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (45 g): $29.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Diprolene AF External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $74.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Betamethasone Valerate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.12% (50 g): $200.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Luxiq External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.12% (50 g): $223.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Betamethasone Dipropionate Aug External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $61.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Betamethasone Dipropionate Aug External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 mL): $60.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Betamethasone Dipropionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 mL): $45.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Betamethasone Valerate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (60 mL): $72.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Diprolene External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 mL): $85.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Betamethasone Dipropionate Aug External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $63.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Betamethasone Dipropionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $43.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Betamethasone Valerate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 g): $20.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Diprolene External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $74.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Celestone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6 mg/5 mL (118 mL): $73.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Betamethasone Sod Phos &amp; Acet Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 (3-3) mg/mL (5 mL): $40.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Celestone Soluspan Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 (3-3) mg/mL (5 mL): $42.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11249451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Growth in children",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F140634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antroquoril (AU);",
"     </li>",
"     <li>",
"      Beavate (MY);",
"     </li>",
"     <li>",
"      Beisong (CL);",
"     </li>",
"     <li>",
"      Bemon (DE);",
"     </li>",
"     <li>",
"      Benosone (MY);",
"     </li>",
"     <li>",
"      Besone (MY, TH);",
"     </li>",
"     <li>",
"      Beta cream (NZ);",
"     </li>",
"     <li>",
"      Beta ointment (NZ);",
"     </li>",
"     <li>",
"      Beta Scalp (NZ);",
"     </li>",
"     <li>",
"      Betacin (PH);",
"     </li>",
"     <li>",
"      Betacort (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Betacorten (IL, SG);",
"     </li>",
"     <li>",
"      Betaderm (AE, BH, CY, EG, HK, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, VE, YE);",
"     </li>",
"     <li>",
"      Betagalen (DE);",
"     </li>",
"     <li>",
"      Betamamallet (JP);",
"     </li>",
"     <li>",
"      Betasone (HK);",
"     </li>",
"     <li>",
"      Betaval (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Betesil (FR);",
"     </li>",
"     <li>",
"      Betesil Plaster (GB);",
"     </li>",
"     <li>",
"      Betnelan V (BE);",
"     </li>",
"     <li>",
"      Betnesol (LU);",
"     </li>",
"     <li>",
"      Betnesol V (DE);",
"     </li>",
"     <li>",
"      Betneval (FR);",
"     </li>",
"     <li>",
"      Betnovat (DK, NO, SE);",
"     </li>",
"     <li>",
"      Betnovate (AE, AT, AU, BB, BF, BG, BH, BJ, BM, BR, BS, BZ, CI, CN, CR, CY, CZ, DO, EE, EG, ES, ET, GB, GH, GM, GN, GR, GT, GY, HK, HN, IL, IN, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, NZ, OM, PA, PE, PH, PK, PR, PT, QA, SA, SC, SD, SG, SL, SN, SR, SV, SY, TH, TN, TR, TT, TZ, UG, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Betonate (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Betopic (TW);",
"     </li>",
"     <li>",
"      Bettamousse (IL);",
"     </li>",
"     <li>",
"      Camnovate (SG);",
"     </li>",
"     <li>",
"      Celestan V (DE);",
"     </li>",
"     <li>",
"      Celestoderm (CO, FI);",
"     </li>",
"     <li>",
"      Celestoderm V (CH, ES, IT);",
"     </li>",
"     <li>",
"      Celestoderm-V (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Celestone (500 mcg) (BO);",
"     </li>",
"     <li>",
"      Celestone (HU, LU, MX);",
"     </li>",
"     <li>",
"      Celestone-M (AU);",
"     </li>",
"     <li>",
"      Clinivate (TH);",
"     </li>",
"     <li>",
"      Cortipyren (UY);",
"     </li>",
"     <li>",
"      Cortival (AU);",
"     </li>",
"     <li>",
"      Crinex (PY);",
"     </li>",
"     <li>",
"      Cronolevel (MX);",
"     </li>",
"     <li>",
"      Dendri (KP);",
"     </li>",
"     <li>",
"      Dermasone (SG);",
"     </li>",
"     <li>",
"      Dermobet (BR);",
"     </li>",
"     <li>",
"      Dermocort (BG);",
"     </li>",
"     <li>",
"      Derzid (HK, SG);",
"     </li>",
"     <li>",
"      Diprofast (MX);",
"     </li>",
"     <li>",
"      Diprolene (NL, PL);",
"     </li>",
"     <li>",
"      Dipronova (MX);",
"     </li>",
"     <li>",
"      Diprosone (AR, IE, MX, NL, PL);",
"     </li>",
"     <li>",
"      Diprospan (MX);",
"     </li>",
"     <li>",
"      Erispan (MX);",
"     </li>",
"     <li>",
"      Hexoderm (PY);",
"     </li>",
"     <li>",
"      Hormezone (JP);",
"     </li>",
"     <li>",
"      Inflacor (EC);",
"     </li>",
"     <li>",
"      Lenovate (ZA);",
"     </li>",
"     <li>",
"      Medobeta (SG);",
"     </li>",
"     <li>",
"      Molason (ID);",
"     </li>",
"     <li>",
"      Polynovate (TH);",
"     </li>",
"     <li>",
"      Repivate (ZA);",
"     </li>",
"     <li>",
"      Sanbetason (JP);",
"     </li>",
"     <li>",
"      Sebo Scalp Tonic (TH);",
"     </li>",
"     <li>",
"      Uniflex (PH);",
"     </li>",
"     <li>",
"      Varol (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F140611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F140627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 64%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 6.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.V.: 10-36 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;5% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Obstetric Practice, \"ACOG Committee Opinion No. 475: Antenatal Corticosteroid Therapy for Fetal Maturation,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(2 Pt 1):422-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/21252775/pubmed\" id=\"21252775\" target=\"_blank\">",
"        21252775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boot AM, Nauta J, Hokken-Koelega AC, et al, &ldquo;Renal Transplantation and Osteoporosis,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1995, 72(6):502-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/7618934/pubmed\" id=\"7618934\" target=\"_blank\">",
"        7618934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bowman H and Lennard TW, &ldquo;Immunosuppressive Drugs,&rdquo;",
"      <i>",
"       Br J Hosp Med",
"      </i>",
"      , 1992, 48(9):570-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/1282440/pubmed\" id=\"1282440\" target=\"_blank\">",
"        1282440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Committee on Obstetric Practice, &ldquo;ACOG Committee Opinion: Antenatal Corticosteroid Therapy for Fetal Maturation,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2002, 99(5 Pt 1):871-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/11978304/pubmed\" id=\"11978304\" target=\"_blank\">",
"        11978304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper MS and Stewart PM, &ldquo;Corticosteroid Insufficiency in Acutely Ill Patients,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/12594318/pubmed\" id=\"12594318\" target=\"_blank\">",
"        12594318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coursin DB and Wood KE, &ldquo;Corticosteroid Supplementation for Adrenal Insufficiency,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 287(2):236-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/11779267/pubmed\" id=\"11779267\" target=\"_blank\">",
"        11779267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gamsu HR, Mullinger BM, Donnai P, et al, &ldquo;Antenatal Administration of Betamethasone to Prevent Respiratory Distress Syndrome in Preterm Infants: Report of a UK Multicentre Trial,&rdquo;",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1989, 96(4):401-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/2665800/pubmed\" id=\"2665800\" target=\"_blank\">",
"        2665800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grotz WH, Mundinger FA, Gugel B, et al, &ldquo;Bone Mineral Density After Kidney Transplantation: A Cross-Sectional Study in 190-Graft Recipients Up to 20 Years After Transplantation,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1995, 59(7):982-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/7709459/pubmed\" id=\"7709459\" target=\"_blank\">",
"        7709459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gutin PH, &ldquo;Corticosteroid Therapy in Patients With Brain Tumors,&rdquo;",
"      <i>",
"       Natl Cancer Inst Monogr",
"      </i>",
"      , 1977, 46:151-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/349394/pubmed\" id=\"349394\" target=\"_blank\">",
"        349394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henderson JJ, Hartmann PE, Newnham JP, et al, &ldquo;Effect of Preterm Birth and Antenatal Corticosteroid Treatment on Lactogenesis II in Women,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(1):e92-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/18166549/pubmed\" id=\"18166549\" target=\"_blank\">",
"        18166549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kimberly RP, &ldquo;Glucocorticoids,&rdquo;",
"      <i>",
"       Curr Opin Rheumatol",
"      </i>",
"      , 1994, 6(3):273-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/8060761/pubmed\" id=\"8060761\" target=\"_blank\">",
"        8060761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liggins GC and Howie RN, &ldquo;A Controlled Trial of Antepartum Glucocorticoid Treatment of Respiratory Distress Syndrome in Premature Infants,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1972, 50(4):515-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/4561295/pubmed\" id=\"4561295\" target=\"_blank\">",
"        4561295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lowenthal RM and Jestrimski KW, &ldquo;Corticosteroid Drugs: Their Role in Oncological Practice,&rdquo;",
"      <i>",
"       Med J Aust",
"      </i>",
"      , 1986, 144(2):81-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/2417096/pubmed\" id=\"2417096\" target=\"_blank\">",
"        2417096",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGee S and Hirschmann J, &ldquo;Use of Corticosteroids in Treating Infectious Diseases,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2008, 168(10):1034-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/18504331/pubmed\" id=\"18504331\" target=\"_blank\">",
"        18504331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murphy CM, Coonce SL, and Simon PA, &ldquo;Treatment of Asthma in Children,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1991, 10(9):685-703.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/1680599/pubmed\" id=\"1680599\" target=\"_blank\">",
"        1680599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murphy VE, Fittock RJ, Zarzycki PK, et al, &ldquo;Metabolism of Synthetic Steroids by the Human Placenta,&rdquo;",
"      <i>",
"       Placenta",
"      </i>",
"      , 2007, 28(1):39-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/16549198/pubmed\" id=\"16549198\" target=\"_blank\">",
"        16549198",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ostensen M, &ldquo;Optimisation of Antirheumatic Drug Treatment in Pregnancy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(6):486-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/7882637/pubmed\" id=\"7882637\" target=\"_blank\">",
"        7882637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo;",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(12):968-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/14745915/pubmed\" id=\"14745915\" target=\"_blank\">",
"        14745915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed, BR, &ldquo;Dermatologic Drugs, Pregnancy, and Lactation. A Conservative Guide,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1997, 133(7):894-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/9236528/pubmed\" id=\"9236528\" target=\"_blank\">",
"        9236528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians, &ldquo;Consensus Statement on Management and Audit Potential for Steroid Responsive Nephrotic Syndrome,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1994, 70(2):151-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/5/44120/abstract-text/8129444/pubmed\" id=\"8129444\" target=\"_blank\">",
"        8129444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9139 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-B6EAAB5947-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44120=[""].join("\n");
var outline_f43_5_44120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140644\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140645\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140691\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140649\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140670\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140650\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140651\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140621\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140608\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140625\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140698\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140624\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6495893\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140700\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140689\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140628\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140612\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140684\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140617\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140640\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140618\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140631\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140654\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140632\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140633\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140630\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11249451\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140634\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140611\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140627\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9139\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9139|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/7/7287?source=related_link\">",
"      Betamethasone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/7/28791?source=related_link\">",
"      Betamethasone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_5_44121="Nevoid basal cell carcinoma syndrome";
var content_f43_5_44121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nevoid basal cell carcinoma syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/5/44121/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/5/44121/contributors\">",
"     Benjamin Barankin, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/5/44121/contributors\">",
"     Gary Goldenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/5/44121/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/5/44121/contributors\">",
"     Robert S Stern, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/5/44121/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/5/44121/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/5/44121/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/5/44121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nevoid basal cell carcinoma syndrome (NBCCS) is a rare inherited multisystem disorder that is due to germline mutations in the human homolog of the patched (PTCH) gene. The estimated prevalence is between 1 in 57,000 and 1 in 164,000 persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    First reported in 1894, the clinical manifestations of NBCCS were more clearly defined in 1960 by Gorlin and Goltz [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/4\">",
"     4",
"    </a>",
"    ]. Affected patients have multiple developmental anomalies and the early onset of multiple nevoid basal cell cancers (BCCs) and medulloblastomas, usually by age 35 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/5\">",
"     5",
"    </a>",
"    ]. Other synonyms for NBCCS include the Gorlin or Gorlin-Goltz syndrome, basal cell nevus syndrome, bifid-rib basal-cell nevus syndrome, basal cell cancer syndrome, and multiple basal cell nevi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULAR GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NBCCS is inherited as an autosomal dominant trait with a high degree of penetrance (approximately 97 percent), but variably expressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/6\">",
"     6",
"    </a>",
"    ]. The cause is a germline inactivating mutation involving the human homolog of the Drosophila PTCH1 (patched) gene, which is located on chromosome 9q22.3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/2,7-10\">",
"     2,7-10",
"    </a>",
"    ]. In most cases, loss of function mutations in PTCH1 result in premature termination of the PTCH protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Loss of heterozygosity at this site in both hereditary and sporadic BCCs suggests that it functions as a tumor suppressor gene (see",
"    <a class=\"local\" href=\"#H5\">",
"     'PTCH1 in sporadic basal cell cancers'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/15\">",
"     15",
"    </a>",
"    ]. In a manner similar to the retinoblastoma gene, two somatic \"hits\" in the same cell appear to be required for sporadic cases, while one somatic \"hit\" plus the inheritance of one defective allele underlies familial cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27018?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of retinoblastoma\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Molecular pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only known function of the PTCH protein is as a receptor for the hedgehog (HH) protein, a component of the sonic hedgehog (SHH) signaling pathway (",
"    <a class=\"graphic graphic_figure graphicRef76029 \" href=\"mobipreview.htm?37/41/38554\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This pathway is important in determining tissue patterning and cell fate in multiple structures within the developing embryo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. SHH signaling is activated when HH binds to its receptor, a complex that is formed by PTCH and a second protein, Smoothened (SMO), a transmembrane protein (",
"    <a class=\"graphic graphic_figure graphicRef69105 \" href=\"mobipreview.htm?13/37/13904\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. PTCH functions as a regulatory molecule for SMO, with PTCH-induced repression of SMO limiting the effect of the SHH signal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/20,23\">",
"     20,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to this model, SMO repression is relieved following mutational inactivation of PTCH1 in patients with NBCCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/24\">",
"     24",
"    </a>",
"    ]. This results in constitutive overexpression of the SHH signal, which has been implicated in the development of BCC and other tumors, possibly via activation of the transcription factors Gli1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Gli2 (",
"    <a class=\"graphic graphic_figure graphicRef76029 \" href=\"mobipreview.htm?37/41/38554\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/18,20,25-28\">",
"     18,20,25-28",
"    </a>",
"    ]. The evidence to support a link between overexpression of the SHH pathway and tumorigenesis is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transgenic mice overexpressing SMO or SHH in the skin spontaneously produce skin lesions resembling human BCCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/24,29\">",
"       24,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Owing to failure of negative feedback, the mutant PTCH1 transcript is overexpressed in affected tissues. Such transcripts are found at high levels in the BCCs and odontogenic keratocysts from patients with NBCCS, but not in skin or other types of tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/30-32\">",
"       30-32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Influence of race",
"    </span>",
"    &nbsp;&mdash;&nbsp;Race appears to influence the incidence of NBCCS and also modulates its penetrance. Only about 5 percent of all NBCCS case reports involve blacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/33\">",
"     33",
"    </a>",
"    ], and a similar low frequency is reported in Asians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The expression of cutaneous BCCs as a component of the NBCCS appears to be blunted in individuals with dark skin as well as Asians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Only about 30 to 38 percent of black persons with NBCCS have BCCs (compared to 75 to 80 percent in Caucasians, (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical findings'",
"    </a>",
"    below)), and fewer than 15 percent have more than two BCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/36\">",
"     36",
"    </a>",
"    ]. Because of this, most black patients with NBCCS are diagnosed by asymptomatic odontogenic cysts discovered during routine dental or facial radiography rather than by the appearance of BCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     PTCH1 in sporadic basal cell cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support for the involvement of PTCH1 in tumorigenesis is supported by the finding of acquired PTCH1 mutations in approximately one-third of sporadic BCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], in xeroderma pigmentosum-associated BCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/40\">",
"     40",
"    </a>",
"    ], as well as some sporadic meningiomas and medulloblastomas. In sporadic BCCs, inactivation of the PTCH1 gene appears to be a necessary but insufficient step for tumor formation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=see_link\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41332?source=see_link\">",
"     \"Histopathology and molecular pathogenesis of medulloblastoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=see_link&amp;anchor=H523750964#H523750964\">",
"     \"The genodermatoses\", section on 'Xeroderma pigmentosum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism responsible for PTCH mutations in sporadic BCCs is probably multifactorial. Exposure to ultraviolet (UV) light is an important risk factor for early onset BCCs, and the PTCH gene appears to be a target for UV-induced mutations. However, typical UV signature mutations are found in only 30 to 40 percent of PTCH1-mutated sporadic BCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/14\">",
"     14",
"    </a>",
"    ], while they are more prominent in the BCCs of patients with xeroderma pigmentosum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/40\">",
"     40",
"    </a>",
"    ]. Thus, mutational events other than UV irradiation may also cause PTCH inactivation and trigger tumorigenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other mutational events affecting the SHH pathway have also been implicated in the development of sporadic BCCs. These include activating mutations in the SMO gene, a reciprocal translocation between chromosomes 9q22.3 (the site of the PTCH1 gene) and 16p, and mutations in a second PTCH gene, PTCH2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/24,41-43\">",
"     24,41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 100 clinical abnormalities have been reported in NBCCS. The major manifestations are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early development of multiple BCCs",
"     </li>",
"     <li>",
"      Odontogenic (bone) keratocysts, especially in the mandible",
"     </li>",
"     <li>",
"      Palmar and plantar pitting (",
"      <a class=\"graphic graphic_picture graphicRef72687 \" href=\"mobipreview.htm?25/24/25989\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ectopic intracranial calcification, most often of the falx cerebri [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Family history of NBCCS",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Minor criteria include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Craniofacial anomalies (macrocephaly, frontal bossing, hypertelorism)",
"     </li>",
"     <li>",
"      Bifid ribs",
"     </li>",
"     <li>",
"      Early onset medulloblastomas (3 to 5 percent)",
"     </li>",
"     <li>",
"      Cardiac or ovarian fibromas, often bilateral",
"     </li>",
"     <li>",
"      Lymphomesenteric cysts",
"     </li>",
"     <li>",
"      Congenital malformations (cleft",
"      <span class=\"nowrap\">",
"       lip/palate,",
"      </span>",
"      polydactyly, eye abnormalities, colobomas, cataracts, glaucoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of the major clinical findings (BCCs, jaw cysts, macrocephaly, palmoplantar pits) is between 75 and 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/3,45\">",
"     3,45",
"    </a>",
"    ]. Although medulloblastomas (which are characteristically of the desmoplastic subtype) tend to develop at a young age, many of the classic features of NBCCS (ie, BCCs, palmar pits, calcified falx cerebri) may not be detected until the late teens or young adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41332?source=see_link\">",
"     \"Histopathology and molecular pathogenesis of medulloblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Basal cell cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;BCCs are found in about three-fourths of all affected Caucasian patients with NBCCS, but are less frequent in affected blacks and Asians (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Influence of race'",
"    </a>",
"    above). Age at first diagnosis ranges from 3 to 53 years old with an average age of 20 to 21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of BCCs can vary from only a few to thousands, and they range in size from 1 to 10 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/48\">",
"     48",
"    </a>",
"    ]. While BCCs frequently occur on sun-exposed areas such as the head, neck, back, chest, and upper limbs, they can occur in any location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/3,49\">",
"     3,49",
"    </a>",
"    ]. BCCs arising in NBCCS are histologically indistinguishable from sporadic BCCs. The term \"nevoid\" does not refer to an association of the BCC with nevi, but instead was coined because early lesions may have the appearance of nevi with a prominent vascular component.",
"   </p>",
"   <p>",
"    BCCs tend to be more aggressive in patients with the NBCCS. Despite this, only a small fraction become locally invasive, and they do so only after puberty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/48\">",
"     48",
"    </a>",
"    ]. Rarely, patients with NBCCS die as a result of local invasion into brain or lung, or distant metastatic spread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sun exposure &mdash; Sun exposure is the most important environmental cause of BCC in the general population. However, the relationship between sun exposure and the development of BCCs in patients with NBCCS is unclear. The anatomic site distribution of BCCs suggests that frequent sun exposure may not be essential for the development of BCCs in affected patients. However, the observation that there are more tumors on sun-exposed areas suggests that exposure promotes the development of BCCs in patients with NBCCS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=see_link&amp;anchor=H3#H3\">",
"       \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation therapy &mdash; Superficial therapeutic radiation, as for psoriasis, increases the risk of nonmelanoma skin cancers, including BCC. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=see_link&amp;anchor=H3#H3\">",
"       \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Risk factors'",
"      </a>",
"      .) Patients with NBCCS are particularly sensitive to the effects of ionizing radiation, and the development of multiple BCCs within irradiated fields in affected patients is well described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/49,52-55\">",
"       49,52-55",
"      </a>",
"      ]. DNA synthesis is abnormally induced in irradiated NBCCS cells, and this abnormality may supply the subsequent mutation necessary for tumor development in NBCCS patients who have been exposed to ionizing radiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. Because of this, RT is generally avoided in patients with NBCCS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24712?source=see_link&amp;anchor=H12329838#H12329838\">",
"       \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Radiation therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Odontogenic (jaw) keratocysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Odontogenic keratocysts are cystic lesions of the bone that are lined with keratinized epithelium and thought to originate from the dental lamina. Despite their bland histology, these lesions are locally destructive with heparanase expression, perhaps correlated with the neoplastic properties of NBCCS-associated odontogenic keratocysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/58\">",
"     58",
"    </a>",
"    ]. They are neoplastic rather than developmental in origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/59\">",
"     59",
"    </a>",
"    ] and are characterized by aggressive clinical behavior, including involvement of the teeth and a recurrence rate that is as high as 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence can result from incomplete removal, remnants of dental lamina within the jaw, or the presence of satellite cysts. NBCCS keratocysts have a different immunophenotype from sporadic keratocysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/61\">",
"     61",
"    </a>",
"    ]. A 10-year retrospective analysis of 83 patients with odontogenic keratocysts identified six patients (8 percent) with a total of 15 lesions who had NBCCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cysts usually develop after the age of seven and peak during the second or third decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/44,48\">",
"     44,48",
"    </a>",
"    ], but they have been reported in children as young as four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/36\">",
"     36",
"    </a>",
"    ]. The number of jaw cysts averages six (reported range, 1 to 28) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/3,36\">",
"     3,36",
"    </a>",
"    ], unlike with sporadic cases where they are typically solitary. Unlike BCCs, there is no racial predilection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three-fourths of odontogenic keratocysts present in the mandible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/36,63\">",
"     36,63",
"    </a>",
"    ]. The most common locations in decreasing frequency are the mandibular third molar region, maxillary third molar region, and mandibular first and second molar region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/64\">",
"     64",
"    </a>",
"    ]. Approximately one-third are asymptomatic and are detected on routine dental examination, while 50 percent present with jaw swelling, 25 percent with mild pain, and 15 percent with altered taste [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is discussed below (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Odontogenic keratocysts'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Palmar-plantar pits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palmar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plantar pits are highly characteristic of NBCCS, occurring in approximately 80 percent of affected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/36,66\">",
"     36,66",
"    </a>",
"    ]. They are asymptomatic nonpalpable shallow depressions (1 to 3 mm) in the skin of the palm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    soles that are due to partial or complete absence of stratum corneum (",
"    <a class=\"graphic graphic_figure graphicRef76029 \" href=\"mobipreview.htm?37/41/38554\">",
"     figure 1",
"    </a>",
"    ). They may also be found on the sides, web spaces, and dorsum of the fingers and toes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/67\">",
"     67",
"    </a>",
"    ]. The differential diagnosis should consider punctate keratoderma, pitted keratolysis, and palmar pits of Darier's disease, but the clinical distinction is usually easy.",
"   </p>",
"   <p>",
"    Pitting generally develops during the patient's 20s and later, but has been reported in much younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/49\">",
"     49",
"    </a>",
"    ]. In contrast to BCC, there is no racial difference in the frequency of pitting in affected patients with NBCCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/33\">",
"     33",
"    </a>",
"    ]. The number of pits is variable but can reach more than 500 in number, particularly in older individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/67\">",
"     67",
"    </a>",
"    ]. They are permanent, and do not wax and wane over time. Soaking the hands in water for 10 to 15 minutes can make their appearance more pronounced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Brain tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medulloblastomas characteristically arise in the midline in the area of the cerebellar vermis. Meningiomas are the next most common brain tumors developing in patients with NBCCS, although they are much less common than medulloblastoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/48,68\">",
"     48,68",
"    </a>",
"    ]. Other tumors and cysts involving the brain have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25540?source=see_link\">",
"     \"Meningioma: Clinical presentation and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of medulloblastoma in patients with NBCCS is 5 percent or less, and there is a male predominance of 3:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In contrast to sporadic medulloblastomas, which most commonly present between the ages of 6 and 10, medulloblastomas characteristically present by age two in individuals with NBCCS. This syndrome should be considered in any atypically young child with medulloblastoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41332?source=see_link\">",
"     \"Histopathology and molecular pathogenesis of medulloblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intracranial ectopic calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 65 percent of affected persons have calcification of the falx cerebri, but this increases to 80 to 90 percent of those over the age of 40 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/36,47\">",
"     36,47",
"    </a>",
"    ]. Other areas of ectopic calcification include the diaphragma sellae in 60 to 80 percent (with complete or partial bridging of the sella turcica), the tentorium cerebelli in 40 percent, and the petroclinoid ligament in 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Characteristic facies and body habitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with NBCCS have a characteristic \"coarse\" facial appearance consisting of frontal bossing, macrocephaly (80 percent), hypertelorism (5 percent), high arched eyebrows (40 percent) and palate, widened nasal bridge (60 percent), and mandibular prognathism (35 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/3,5,36,48,72\">",
"     3,5,36,48,72",
"    </a>",
"    ]. In 50 to 60 percent of affected individuals, there are milia scattered on the face among the BCCs. Approximately 15 percent of patients are very tall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cardiac fibromas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac fibromas are increased in frequency in patients with NBCCS, developing in approximately 3 percent of affected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/46\">",
"     46",
"    </a>",
"    ]. These are benign growths, and almost all develop within the ventricular myocardium. Although usually asymptomatic, cardiac fibromas can result in impaired left ventricular function and conduction defects, necessitating resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=see_link\">",
"     \"Cardiac tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ovarian fibromas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian fibromas develop in 15 to 25 percent of girls with NBCCS, and are often calcified and bilateral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/3,36,46,75\">",
"     3,36,46,75",
"    </a>",
"    ]. Other ovarian tumors including fibrosarcomas are rarely reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/36/8778?source=see_link&amp;anchor=H19#H19\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\", section on 'Fibroma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bone abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occult skeletal abnormalities are frequent in patients with BCCS. Between 38 to 60 percent have rib abnormalities including bifid ribs, marked widening of the anterior rib ends, and fusion and modeling defects of the ribs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/36,48,77\">",
"     36,48,77",
"    </a>",
"    ]. Occult spina bifida may be seen as a component of NBCCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/77\">",
"     77",
"    </a>",
"    ], although it has not been documented in all series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mesenteric cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single or multiple lymphomesenteric cysts may be seen as a component of NBCCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/75\">",
"     75",
"    </a>",
"    ]. They tend to calcify and are usually asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Skin tags",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of skin tags in a child may be a clue as to the diagnosis of NBCCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/78\">",
"     78",
"    </a>",
"    ]. Biopsy should be considered within the clinical context.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the reported ocular anomalies in patients with NBCCS are congenital cataracts, colobomas (involving the choroids and optic nerve), nystagmus, strabismus, hypertelorism, and telecanthus (10 to 25 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/36,46,48\">",
"     36,46,48",
"    </a>",
"    ]. Cleft palate is seen in approximately 5 percent of affected individuals.",
"   </p>",
"   <p>",
"    Both pectus deformities and Sprengel deformity (narrow sloping shoulders) are more common in individuals with NBCCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/3,36\">",
"     3,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=see_link\">",
"     \"Diseases of the chest wall\"",
"    </a>",
"    .) Approximately 10 percent of patients have anosmia, which may be a sign of hypogonadotropic hypogonadism; other hypogonadal features include cryptorchidism, gynecomastia, and scanty facial or body hair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/3,79\">",
"     3,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minor kidney abnormalities, often diagnosed incidentally or at autopsy, are seen in about 5 percent of patients with NBCCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/48\">",
"     48",
"    </a>",
"    ]. Scattered case reports indicate the occasional association of other neoplasms with NBCCS including fetal rhabdomyoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/75,80\">",
"     75,80",
"    </a>",
"    ], non-Hodgkin lymphoma, Hodgkin lymphoma, melanoma, chronic lymphoid leukemia, soft tissue leiomyosarcoma, breast and lung carcinoma, and sinonasal undifferentiated carcinoma (SNUC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of NBCCS is a clinical one with the diagnosis being supported by finding either two major, or one major and two minor criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/46\">",
"     46",
"    </a>",
"    ]. However, molecular findings (eg, high level of expression of PTCH1 transcripts on odontogenic keratocysts by reverse transcriptase polymerase chain reaction [RT-PCR]) can be used to support the diagnosis in questionable cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC WORKUP",
"    </span>",
"    &nbsp;&mdash;&nbsp;At a minimum, the following studies are indicated in patients suspected of having NBCCS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skull radiograph or CT can demonstrate a calcified falx cerebri, complete or partial bridging of the sella turcica, or a broadened nasal root.",
"     </li>",
"     <li>",
"      Panoramic films are recommended to identify odontogenic keratocysts; MRI may be superior in demonstrating the internal composition and structure of the cysts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chest x-ray to document rib abnormalities (eg, bifid ribs).",
"     </li>",
"     <li>",
"      Hand and foot x-rays will show flame-shaped lucencies (lytic bone lesions) in 30 percent of hand films and 17 percent of foot films [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin biopsy of a basal cell carcinoma will show nodules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    strands of atypical basaloid cells which show nuclear palisading, cellular apoptosis, and scattered mitotic activity in the dermis (",
"    <a class=\"graphic graphic_picture graphicRef68853 graphicRef79258 \" href=\"mobipreview.htm?25/60/26570\">",
"     picture 2A-B",
"    </a>",
"    ). Artifactual cleft formation may be seen between the tumor lobules and the surrounding stroma, which may be mucinous. Solar elastosis is usually present in the dermis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pertinent issues in the management of affected patients include surveillance for the development of syndrome-related complications, and specific treatment for postnatal tumors and odontogenic keratocysts. Most other abnormalities are either cosmetic, incidental, or managed as in patients without this syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;For individuals diagnosed with NBCCS, regular visits to a dermatologist every two to three months is recommended, particularly during adolescence. Annual panoramic radiographs of the jaw are recommended starting at the age of eight, and a cranial MRI to exclude medulloblastoma should be performed annually until the age of eight. Periodically, echocardiography to exclude cardiac fibroma should be performed.",
"   </p>",
"   <p>",
"    For infants with a family history of NBCCS, early diagnosis may be achieved with the use of screening radiography to look for calcification of the falx, rib anomalies, or calcified ovarian fibromas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/3\">",
"     3",
"    </a>",
"    ]. Affected patients should be counseled to minimize exposure to ultraviolet light and avoid therapeutic ionizing irradiation (eg, MRI is preferred over CT), if at all possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment of basal cell cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the large number of lesions, treatment of BCCs in these patients may be extremely difficult. Lesions that are growing or that become invasive should be excised, or curetted and electrodesiccated. More aggressive tumors or those in delicate or high-risk areas benefit from Mohs' micrographic surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13690?source=see_link\">",
"     \"Treatment and prognosis of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24712?source=see_link\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple surgical procedures are often a source of discomfort, pain, and disfigurement for patients with NBCCS. Carbon dioxide laser therapy can be a useful modality in selected patients for tumors in low-risk areas and has shown efficacy in combination with microscopically controlled excision (Mohs micrographic surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/83-87\">",
"     83-87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Topical tretinoin and 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most of the BCCs are nodular, superficial lesions can be managed by topical application of 5 percent 5-fluorouracil (5-FU) with or without 0.1% tretinoin cream (to enhance penetration of 5-FU) applied twice daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/75\">",
"     75",
"    </a>",
"    ]. Tretinoin should be avoided around the eyes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Topical imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports are also emerging that suggest a possible role for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    cream as a less-invasive approach to managing and perhaps preventing development of new BCCs in patients with NBCCS. In several reports, imiquimod 5% cream applied three days per week has shown considerable efficacy for superficial BCCs in affected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/88-92\">",
"     88-92",
"    </a>",
"    ]. In one report, 13 of 17 superficial BCCs were successfully controlled (at least in the short run) after 8 to 14 weeks of three times weekly application [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/90\">",
"     90",
"    </a>",
"    ]. The most common side-effect of topical imiquimod is local erythema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13690?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prognosis of basal cell carcinoma\", section on 'Imiquimod'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the majority of BCCs are nodular in patients with NBCCS.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    is less successful for nodular BCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/88\">",
"     88",
"    </a>",
"    ], although it may be useful in conjunction with curettage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing experience with photodynamic therapy (PDT) in patients with NBCCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/95\">",
"     95",
"    </a>",
"    ]. As with sporadic BCCs, PDT appears most successful for flat lesions, rather than those that are raised or nodular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13690?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment and prognosis of basal cell carcinoma\", section on 'Photodynamic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Chemoprevention with oral retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral retinoids are not useful therapeutically; few lesions objectively regress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. They are used more often for chemoprevention rather than treatment of existing BCCs. However, large trials of systemic retinoids as chemopreventive agents have not been conducted in patients with NBCCS. At least one report suggests that low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    (10 mg daily) is ineffective in preventing additional BCCs in patients who have had two or more sporadic BCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/98\">",
"     98",
"    </a>",
"    ]. Because of the need for moderate to high doses and the limited degree of benefit, oral retinoids are seldom to uncommonly used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Locally advanced and metastatic BCCs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific agents targeting the sonic hedgehog pathway may offer a new approach for patients with metastatic disease or no longer amenable to local therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/99\">",
"     99",
"    </a>",
"    ]. This approach is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14293?source=see_link\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Odontogenic keratocysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, odontogenic cysts frequently recur following surgery. The treatment of choice is wide surgical excision and curettage with extraction of associated teeth by an experienced oral-maxillofacial surgeon or otolaryngologist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/3,48\">",
"     3,48",
"    </a>",
"    ]. Bone and alveolar nerve grafting may be required in some instances. A 10-year retrospective review of 83 cases of odontogenic keratocysts suggests that marsupialization followed by enucleation results in the lowest recurrence rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/62\">",
"     62",
"    </a>",
"    ]. Histopathologic examination of tissue is important because several cases of malignant transformation to squamous cell carcinoma have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/100-102\">",
"     100-102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resolution of odontogenic keratocysts has been reported in a patient treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/59/18357?source=see_link\">",
"     vismodegib",
"    </a>",
"    (GDC-0449), an experimental oral inhibitor of the hedgehog pathway that has been used for the treatment of BCC in patients with NBCCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/103\">",
"     103",
"    </a>",
"    ]. Additional studies are necessary to determine the role of vismodegib in the treatment of odontogenic keratocysts. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Future directions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14293?source=see_link&amp;anchor=H7#H7\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\", section on 'Vismodegib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Medulloblastomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with NBCCS, radiation therapy for medulloblastomas induces hundreds of difficult to manage BCCs; it should be avoided. Often these BCCs are preceded by a \"rash\" from 6 to 36 months following radiation which represents activated BCCs. A sinonasal tumor developing 17 years after initial irradiation of a medulloblastoma has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/104\">",
"     104",
"    </a>",
"    ]. Medulloblastomas may also be treated by surgery and chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2058?source=see_link\">",
"     \"Epidemiology, treatment, and prognosis of medulloblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7649457\">",
"    <span class=\"h2\">",
"     Vitamin D deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synthesis of vitamin D in the skin is inhibited by photoprotective measures, and patients with photosensitive disorders such as NBCCS may have an increased risk for vitamin D deficiency. In a retrospective cohort study of 41 patients with NBCCS, the prevalence of vitamin D deficiency (25[OH]D level &le;20",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    was significantly greater than the prevalence reported in the general population (56 versus 18 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/105\">",
"     105",
"    </a>",
"    ]. Thus, clinicians should be aware of the potential for vitamin D deficiency in patients with NBCCS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=see_link\">",
"     \"Vitamin D and extraskeletal health\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional studies are necessary to evaluate whether disease-specific factors other than photoprotection contribute to vitamin D deficiency in NBCCS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A placebo-controlled randomized trial found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/59/18357?source=see_link\">",
"     vismodegib",
"    </a>",
"    (GDC-0449), an oral hedgehog antagonist, was beneficial for slowing the rate of BCC development and reducing tumor burden in NBCCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/106\">",
"     106",
"    </a>",
"    ]. In the trial, patients with NBCCS were treated with either 150 mg per day of vismodegib (n = 26) or placebo (n = 15) for 1 to 15 months (mean, 8 months). At three months, a significantly lower mean per-patient incidence of new, surgically eligible BCCs (diameter &gt;3 mm on nose or periorbital skin, &gt;5 mm on other facial sites, or &gt;9 mm on the trunk or limbs) was detected in the active treatment group than in the placebo group (2 versus 29 BCCs per year). In addition, tumor size decreased to a greater extent in patients who received vismodegib than in those who received placebo, with a few patients achieving complete remission.",
"   </p>",
"   <p>",
"    Although these findings are promising, adverse effects, such as loss of taste, muscle cramps, hair loss, and weight loss limited the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/59/18357?source=see_link\">",
"     vismodegib",
"    </a>",
"    ; 14 of 26 patients (54 percent) discontinued treatment for this reason. In addition, tumors regrew following drug discontinuation. More studies are required to determine whether vismodegib has the potential to truly cure individual BCCs in NBCCS, as well as to clarify the optimal treatment regimen for vismodegib in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14293?source=see_link&amp;anchor=H7#H7\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\", section on 'Vismodegib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with tumors that appear to respond well to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/59/18357?source=see_link\">",
"     vismodegib",
"    </a>",
"    eventually experience regrowth of tumors despite continued therapy. In a series of 28 patients with a total of 230 advanced and nonadvanced BCCs (including five patients with NBCCS), tumor regrowth during treatment was detected in six patients (21 percent) and affected 5 percent of all tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/107\">",
"     107",
"    </a>",
"    ]. The mean time to tumor regrowth was 56 weeks. The reason for this occurrence is unknown.",
"   </p>",
"   <p>",
"    The topical administration of an inhibitor of the hedgehog pathway may be another future option for the management of patients with NBCCS. In a randomized trial in which 27 BCCs in eight patients with NBCCS were treated with a topical inhibitor of Smoothened or a placebo agent twice daily for four weeks, complete or partial responses were observed in 12 out of 13 lesions treated with the Smoothened inhibitor compared with 1 out of 14 lesions treated with the placebo agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/5/44121/abstract/108\">",
"     108",
"    </a>",
"    ]. The effect of this treatment on BCCs in patients without NBCCS is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant, multisystem disorder, due to mutations in the PTCH1 tumor suppressor gene. &nbsp;(See",
"      <a class=\"local\" href=\"#H2\">",
"       'Molecular genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary manifestation of NBCCS is the development of multiple basal cell carcinomas (BCCs), which are histologically identical to sporadic BCCs. While BCCs frequently occur on sun-exposed areas, they can occur in any location and tend to be more aggressive in patients with NBCCS. Important risk factors for the development of BCCs include sun exposure and radiation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Basal cell cancers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals diagnosed with NBCCS should undergo frequent surveillance by a dermatologist to facilitate early diagnosis of new nevi. The management of BCCs that are diagnosed can be difficult because of the multiplicity of lesions and the need for multiple procedures. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Surveillance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Treatment of basal cell cancers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to BCCs, NBCCS is associated with a variety of other cysts and tumors, including odontogenic keratocysts and medulloblastomas. Therapeutic radiation therapy needs to be avoided in such patients, since this can precipitate the development of numerous, aggressive BCCs. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/1\">",
"      Cohen MM Jr. Nevoid basal cell carcinoma syndrome: molecular biology and new hypotheses. Int J Oral Maxillofac Surg 1999; 28:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/2\">",
"      Farndon PA, Del Mastro RG, Evans DG, Kilpatrick MW. Location of gene for Gorlin syndrome. Lancet 1992; 339:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/3\">",
"      Shanley S, Ratcliffe J, Hockey A, et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet 1994; 50:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/4\">",
"      GORLIN RJ, GOLTZ RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med 1960; 262:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/5\">",
"      Rahbari H, Mehregan AH. Basal cell epithelioma (carcinoma) in children and teenagers. Cancer 1982; 49:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/6\">",
"      Anderson DE, Taylor WB, Falls HF, Davidson RT. The nevoid basal cell carcinoma syndrome. Am J Hum Genet 1967; 19:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/7\">",
"      Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/8\">",
"      Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/9\">",
"      Unden AB, Holmberg E, Lundh-Rozell B, et al. Mutations in the human homologue of Drosophila patched (PTCH) in basal cell carcinomas and the Gorlin syndrome: different in vivo mechanisms of PTCH inactivation. Cancer Res 1996; 56:4562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/10\">",
"      Goldstein AM, Stewart C, Bale AE, et al. Localization of the gene for the nevoid basal cell carcinoma syndrome. Am J Hum Genet 1994; 54:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/11\">",
"      Lam CW, Leung CY, Lee KC, et al. Novel mutations in the PATCHED gene in basal cell nevus syndrome. Mol Genet Metab 2002; 76:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/12\">",
"      Aszterbaum M, Rothman A, Johnson RL, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol 1998; 110:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/13\">",
"      Wicking C, Shanley S, Smyth I, et al. Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident. Am J Hum Genet 1997; 60:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/14\">",
"      Zhang H, Ping XL, Lee PK, et al. Role of PTCH and p53 genes in early-onset basal cell carcinoma. Am J Pathol 2001; 158:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/15\">",
"      Teh MT, Blaydon D, Chaplin T, et al. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res 2005; 65:8597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/16\">",
"      Levanat S, Gorlin RJ, Fallet S, et al. A two-hit model for developmental defects in Gorlin syndrome. Nat Genet 1996; 12:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/17\">",
"      Gailani MR, Bale AE. Developmental genes and cancer: role of patched in basal cell carcinoma of the skin. J Natl Cancer Inst 1997; 89:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/18\">",
"      Booth DR. The hedgehog signalling pathway and its role in basal cell carcinoma. Cancer Metastasis Rev 1999; 18:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/19\">",
"      Grachtchouk V, Grachtchouk M, Lowe L, et al. The magnitude of hedgehog signaling activity defines skin tumor phenotype. EMBO J 2003; 22:2741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/20\">",
"      Dahmane N, Lee J, Robins P, et al. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 1997; 389:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/21\">",
"      Ruiz i Altaba A, S&aacute;nchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2002; 2:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/22\">",
"      Ghali L, Wong ST, Green J, et al. Gli1 protein is expressed in basal cell carcinomas, outer root sheath keratinocytes and a subpopulation of mesenchymal cells in normal human skin. J Invest Dermatol 1999; 113:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/23\">",
"      Alcedo J, Ayzenzon M, Von Ohlen T, et al. The Drosophila smoothened gene encodes a seven-pass membrane protein, a putative receptor for the hedgehog signal. Cell 1996; 86:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/24\">",
"      Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/25\">",
"      Eichberger T, Regl G, Ikram MS, et al. FOXE1, a new transcriptional target of GLI2 is expressed in human epidermis and basal cell carcinoma. J Invest Dermatol 2004; 122:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/26\">",
"      Green J, Leigh IM, Poulsom R, Quinn AG. Basal cell carcinoma development is associated with induction of the expression of the transcription factor Gli-1. Br J Dermatol 1998; 139:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/27\">",
"      Wicking C, Smyth I, Bale A. The hedgehog signalling pathway in tumorigenesis and development. Oncogene 1999; 18:7844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/28\">",
"      Duman-Scheel M, Weng L, Xin S, Du W. Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature 2002; 417:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/29\">",
"      Oro AE, Higgins KM, Hu Z, et al. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 1997; 276:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/30\">",
"      Nagano T, Bito T, Kallassy M, et al. Overexpression of the human homologue of Drosophila patched (PTCH) in skin tumours: specificity for basal cell carcinoma. Br J Dermatol 1999; 140:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/31\">",
"      Zedan W, Robinson PA, Markham AF, High AS. Expression of the Sonic Hedgehog receptor \"PATCHED\" in basal cell carcinomas and odontogenic keratocysts. J Pathol 2001; 194:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/32\">",
"      Ohki K, Kumamoto H, Ichinohasama R, et al. PTC gene mutations and expression of SHH, PTC, SMO, and GLI-1 in odontogenic keratocysts. Int J Oral Maxillofac Surg 2004; 33:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/33\">",
"      Goldstein AM, Pastakia B, DiGiovanna JJ, et al. Clinical findings in two African-American families with the nevoid basal cell carcinoma syndrome (NBCC). Am J Med Genet 1994; 50:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/34\">",
"      Ahn SG, Lim YS, Kim DK, et al. Nevoid basal cell carcinoma syndrome: a retrospective analysis of 33 affected Korean individuals. Int J Oral Maxillofac Surg 2004; 33:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/35\">",
"      Kulkarni P, Brashear R, Chuang TY. Nevoid basal cell carcinoma syndrome in a person with dark skin. J Am Acad Dermatol 2003; 49:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/36\">",
"      Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997; 69:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/37\">",
"      Hall J, Johnston KA, McPhillips JP, et al. Nevoid basal cell carcinoma syndrome in a black child. J Am Acad Dermatol 1998; 38:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/38\">",
"      Gailani MR, St&aring;hle-B&auml;ckdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996; 14:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/39\">",
"      Wolter M, Reifenberger J, Sommer C, et al. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1997; 57:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/40\">",
"      Bodak N, Queille S, Avril MF, et al. High levels of patched gene mutations in basal-cell carcinomas from patients with xeroderma pigmentosum. Proc Natl Acad Sci U S A 1999; 96:5117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/41\">",
"      Jin Y, Merterns F, Persson B, et al. The reciprocal translocation t(9;16)(q22;p13) is a primary chromosome abnormality in basal cell carcinomas. Cancer Res 1997; 57:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/42\">",
"      Smyth I, Narang MA, Evans T, et al. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum Mol Genet 1999; 8:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/43\">",
"      Motoyama J, Takabatake T, Takeshima K, Hui C. Ptch2, a second mouse Patched gene is co-expressed with Sonic hedgehog. Nat Genet 1998; 18:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/44\">",
"      Howell JB, Anderson DE. \"The basal-cell nevus\" by Howell and Caro, January 1959. Commentary: The nevoid basal cell carcinoma syndrome. Arch Dermatol 1982; 118:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/45\">",
"      Lo Muzio L, Nocini PF, Savoia A, et al. Nevoid basal cell carcinoma syndrome. Clinical findings in 37 Italian affected individuals. Clin Genet 1999; 55:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/46\">",
"      Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet 1993; 30:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/47\">",
"      Ratcliffe JF, Shanley S, Ferguson J, Chenevix-Trench G. The diagnostic implication of falcine calcification on plain skull radiographs of patients with basal cell naevus syndrome and the incidence of falcine calcification in their relatives and two control groups. Br J Radiol 1995; 68:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/48\">",
"      Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 1987; 66:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/49\">",
"      Howell JB. Nevoid basal cell carcinoma syndrome. Profile of genetic and environmental factors in oncogenesis. J Am Acad Dermatol 1984; 11:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/50\">",
"      Winkler PA, Guyuron B. Multiple metastases from basal cell naevus syndrome. Br J Plast Surg 1987; 40:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/51\">",
"      Goldstein AM, Bale SJ, Peck GL, DiGiovanna JJ. Sun exposure and basal cell carcinomas in the nevoid basal cell carcinoma syndrome. J Am Acad Dermatol 1993; 29:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/52\">",
"      Frentz G, Munch-Petersen B, Wulf HC, et al. The nevoid basal cell carcinoma syndrome: sensitivity to ultraviolet and x-ray irradiation. J Am Acad Dermatol 1987; 17:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/53\">",
"      O'Malley S, Weitman D, Olding M, Sekhar L. Multiple neoplasms following craniospinal irradiation for medulloblastoma in a patient with nevoid basal cell carcinoma syndrome. Case report. J Neurosurg 1997; 86:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/54\">",
"      Wollenberg A, Peter RU, Przybilla B. Multiple superficial basal cell carcinomas (basalomatosis) following cobalt irradiation. Br J Dermatol 1995; 133:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/55\">",
"      Stavrou T, Bromley CM, Nicholson HS, et al. Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 2001; 23:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/56\">",
"      Fujii K, Suzuki N, Ishijima S, et al. Abnormal DNA synthesis activity induced by X-rays in nevoid basal cell carcinoma syndrome cells. Biochem Biophys Res Commun 1997; 240:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/57\">",
"      Mancuso M, Pazzaglia S, Tanori M, et al. Basal cell carcinoma and its development: insights from radiation-induced tumors in Ptch1-deficient mice. Cancer Res 2004; 64:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/58\">",
"      Katase N, Nagatsuka H, Tsujigiwa H, et al. Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor. J Oral Pathol Med 2007; 36:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/59\">",
"      Agaram NP, Collins BM, Barnes L, et al. Molecular analysis to demonstrate that odontogenic keratocysts are neoplastic. Arch Pathol Lab Med 2004; 128:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/60\">",
"      Meara JG, Shah S, Li KK, Cunningham MJ. The odontogenic keratocyst: a 20-year clinicopathologic review. Laryngoscope 1998; 108:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/61\">",
"      Kol&aacute;r Z, Geierov&aacute; M, Bouchal J, et al. Immunohistochemical analysis of the biological potential of odontogenic keratocysts. J Oral Pathol Med 2006; 35:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/62\">",
"      Habibi A, Saghravanian N, Habibi M, et al. Keratocystic odontogenic tumor: a 10-year retrospective study of 83 cases in an Iranian population. J Oral Sci 2007; 49:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/63\">",
"      Myoung H, Hong SP, Hong SD, et al. Odontogenic keratocyst: Review of 256 cases for recurrence and clinicopathologic parameters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/64\">",
"      Brannon RB. The odontogenic keratocyst. A clinicopathologic study of 312 cases. Part I. Clinical features. Oral Surg Oral Med Oral Pathol 1976; 42:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/65\">",
"      Chenevix-Trench G, Wicking C, Berkman J, et al. Further localization of the gene for nevoid basal cell carcinoma syndrome (NBCCS) in 15 Australasian families: linkage and loss of heterozygosity. Am J Hum Genet 1993; 53:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/66\">",
"      Gutierrez MM, Mora RG. Nevoid basal cell carcinoma syndrome. A review and case report of a patient with unilateral basal cell nevus syndrome. J Am Acad Dermatol 1986; 15:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/67\">",
"      Howell JB, Mehregan AH. Pursuit of the pits in the nevoid basal cell carcinoma syndrome. Arch Dermatol 1970; 102:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/68\">",
"      Mortimer PS, Geaney DP, Liddell K, Dawber RP. Basal cell naevus syndrome and intracranial meningioma. J Neurol Neurosurg Psychiatry 1984; 47:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/69\">",
"      Evans DG, Farndon PA, Burnell LD, et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991; 64:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/70\">",
"      Lacombe D, Chateil JF, Fontan D, Battin J. Medulloblastoma in the nevoid basal-cell carcinoma syndrome: case reports and review of the literature. Genet Couns 1990; 1:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/71\">",
"      Dunnick NR, Head GL, Peck GL, Yoder FW. Nevoid basal cell carcinoma syndrome: radiographic manifestations including cystlike lesions of the phalanges. Radiology 1978; 127:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/72\">",
"      Southwick GJ, Schwartz RA. The basal cell nevus syndrome: disasters occurring among a series of 36 patients. Cancer 1979; 44:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/73\">",
"      Jones KL, Wolf PL, Jensen P, et al. The Gorlin syndrome: a genetically determined disorder associated with cardiac tumor. Am Heart J 1986; 111:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/74\">",
"      Cho JM, Danielson GK, Puga FJ, et al. Surgical resection of ventricular cardiac fibromas: early and late results. Ann Thorac Surg 2003; 76:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/75\">",
"      Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol Clin 1995; 13:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/76\">",
"      Kraemer BB, Silva EG, Sneige N. Fibrosarcoma of ovary. A new component in the nevoid basal-cell carcinoma syndrome. Am J Surg Pathol 1984; 8:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/77\">",
"      Ratcliffe JF, Shanley S, Chenevix-Trench G. The prevalence of cervical and thoracic congenital skeletal abnormalities in basal cell naevus syndrome; a review of cervical and chest radiographs in 80 patients with BCNS. Br J Radiol 1995; 68:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/78\">",
"      Chiritescu E, Maloney ME. Acrochordons as a presenting sign of nevoid basal cell carcinoma syndrome. J Am Acad Dermatol 2001; 44:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/79\">",
"      Wallace DC, Murphy KJ, Kelly L, Ward WH. The basal cell naevus syndrome. Report of a family with anosmia and a case of hypogonadotrophic hypopituitarism. J Med Genet 1973; 10:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/80\">",
"      DiSanto S, Abt AB, Boal DK, Krummel TM. Fetal rhabdomyoma and nevoid basal cell carcinoma syndrome. Pediatr Pathol 1992; 12:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/81\">",
"      Sobota A, Pena M, Santi M, Ali Ahmed A. Undifferentiated sinonasal carcinoma in a patient with nevoid basal cell carcinoma syndrome. Int J Surg Pathol 2007; 15:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/82\">",
"      Palacios E, Serou M, Restrepo S, Rojas R. Odontogenic keratocysts in nevoid basal cell carcinoma (Gorlin's) syndrome: CT and MRI evaluation. Ear Nose Throat J 2004; 83:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/83\">",
"      Doctoroff A, Oberlender SA, Purcell SM. Full-face carbon dioxide laser resurfacing in the management of a patient with the nevoid basal cell carcinoma syndrome. Dermatol Surg 2003; 29:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/84\">",
"      Nouri K, Chang A, Trent JT, Jim&eacute;nez GP. Ultrapulse CO2 used for the successful treatment of basal cell carcinomas found in patients with basal cell nevus syndrome. Dermatol Surg 2002; 28:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/85\">",
"      Grobbelaar AO, Horlock N, Gault DT. Gorlin's syndrome: the role of the carbon dioxide laser in patient management. Ann Plast Surg 1997; 39:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/86\">",
"      Krunic AL, Viehman GE, Madani S, Clark RE. Microscopically controlled surgical excision combined with ultrapulse CO2 vaporization in the management of a patient with the nevoid basal cell carcinoma syndrome. J Dermatol 1998; 25:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/87\">",
"      Kopera D, Cerroni L, Fink-Puches R, Kerl H. Different treatment modalities for the management of a patient with the nevoid basal cell carcinoma syndrome. J Am Acad Dermatol 1996; 34:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/88\">",
"      Micali G, De Pasquale R, Caltabiano R, et al. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report. J Dermatolog Treat 2002; 13:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/89\">",
"      Stockfleth E, Ulrich C, Hauschild A, et al. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol 2002; 12:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/90\">",
"      Micali G, Lacarrubba F, Nasca MR, De Pasquale R. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome. Clin Exp Dermatol 2003; 28 Suppl 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/91\">",
"      Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 2000; 26:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/92\">",
"      Vereecken P, Monsieur E, Petein M, Heenen M. Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome. J Dermatolog Treat 2004; 15:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/93\">",
"      Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/94\">",
"      Neville JA, Williford PM, Jorizzo JL. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol 2007; 6:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/95\">",
"      Chapas AM, Gilchrest BA. Broad area photodynamic therapy for treatment of multiple basal cell carcinomas in a patient with nevoid basal cell carcinoma syndrome. J Drugs Dermatol 2006; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/96\">",
"      Peck GL, DiGiovanna JJ, Sarnoff DS, et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 1988; 19:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/97\">",
"      Sanchez-Conejo-Mir J, Camacho F. Nevoid basal cell carcinoma syndrome: combined etretinate and surgical treatment. J Dermatol Surg Oncol 1989; 15:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/98\">",
"      Tangrea JA, Edwards BK, Taylor PR, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst 1992; 84:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/99\">",
"      Goldberg LH, Firoz BF, Weiss GJ, et al. Basal cell nevus syndrome: a brave new world. Arch Dermatol 2010; 146:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/100\">",
"      Anand VK, Arrowood JP Jr, Krolls SO. Malignant potential of the odontogenic keratocyst. Otolaryngol Head Neck Surg 1994; 111:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/101\">",
"      Goldenberg D, Sciubba J, Koch W, Tufano RP. Malignant odontogenic tumors: a 22-year experience. Laryngoscope 2004; 114:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/102\">",
"      Scheer M, Koch AM, Drebber U, K&uuml;bler AC. Primary intraosseous carcinoma of the jaws arising from an odontogenic cyst--a case report. J Craniomaxillofac Surg 2004; 32:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/103\">",
"      Goldberg LH, Landau JM, Moody MN, et al. Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449. Arch Dermatol 2011; 147:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/104\">",
"      Wallin JL, Tanna N, Misra S, et al. Sinonasal carcinoma after irradiation for medulloblastoma in nevoid basal cell carcinoma syndrome. Am J Otolaryngol 2007; 28:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/105\">",
"      Tang JY, Wu A, Linos E, et al. High prevalence of vitamin D deficiency in patients with basal cell nevus syndrome. Arch Dermatol 2010; 146:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/106\">",
"      Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/107\">",
"      Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol 2012; 148:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/5/44121/abstract/108\">",
"      Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011; 131:1735.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5340 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-A0D016103C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44121=[""].join("\n");
var outline_f43_5_44121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULAR GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Influence of race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PTCH1 in sporadic basal cell cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Basal cell cancers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Odontogenic (jaw) keratocysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Palmar-plantar pits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Brain tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intracranial ectopic calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Characteristic facies and body habitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cardiac fibromas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ovarian fibromas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bone abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mesenteric cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Skin tags",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSTIC WORKUP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment of basal cell cancers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Topical tretinoin and 5-FU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Topical imiquimod",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Chemoprevention with oral retinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Locally advanced and metastatic BCCs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Odontogenic keratocysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Medulloblastomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7649457\">",
"      Vitamin D deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Future directions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5340\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5340|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/41/38554\" title=\"figure 1\">",
"      Hedgehog pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/37/13904\" title=\"figure 2\">",
"      Shh Gli pathway medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5340|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/24/25989\" title=\"picture 1\">",
"      Palmar pits BCC nevus syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/63/7158\" title=\"picture 2A\">",
"      Nodular BCC 10x",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/59/11192\" title=\"picture 2B\">",
"      Nodular BCC 20x",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2058?source=related_link\">",
"      Epidemiology, treatment, and prognosis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41332?source=related_link\">",
"      Histopathology and molecular pathogenesis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25540?source=related_link\">",
"      Meningioma: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/36/8778?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14293?source=related_link\">",
"      Systemic treatment of advanced cutaneous squamous and basal cell carcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13690?source=related_link\">",
"      Treatment and prognosis of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24712?source=related_link\">",
"      Treatment of basal cell carcinomas at high risk for recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=related_link\">",
"      Vitamin D and extraskeletal health",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_5_44122="CDC weight for age girls 0 to 36 months";
var content_f43_5_44122=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74314%7EPEDS%2F50020%7EPEDS%2F59076%7EPEDS%2F74789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74314%7EPEDS%2F50020%7EPEDS%2F59076%7EPEDS%2F74789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, girls, birth to 36 months, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 658px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 585px\">",
"   <div class=\"ttl\">",
"    Length-for-age percentiles, girls, birth to 36 months, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 565px; height: 677px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Head circumference-for-age percentiles, girls 0 to 36 months, CDC growth charts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 756px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Weight-for-length percentiles, girls, birth to 36 months, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 672px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44122=[""].join("\n");
var outline_f43_5_44122=null;
var title_f43_5_44123="Vaginal cancer survival";
var content_f43_5_44123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Survival by FIGO stage for patients with vaginal cancer: 1999 to 2001 FIGO statistics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Patients (n)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Overall survival (percent) at",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        1 year",
"       </td>",
"       <td class=\"subtitle2\">",
"        2 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        93.5",
"       </td>",
"       <td>",
"        90.3",
"       </td>",
"       <td>",
"        90.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        91.3",
"       </td>",
"       <td>",
"        87.7",
"       </td>",
"       <td>",
"        77.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        78.7",
"       </td>",
"       <td>",
"        64.9",
"       </td>",
"       <td>",
"        52.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        75.3",
"       </td>",
"       <td>",
"        58.9",
"       </td>",
"       <td>",
"        42.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IVa",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        72.7",
"       </td>",
"       <td>",
"        45.5",
"       </td>",
"       <td>",
"        20.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IVb",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        71.4",
"       </td>",
"       <td>",
"        42.9",
"       </td>",
"       <td>",
"        12.9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. From: Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the vagina. Int J Gynaecol Obstet 2006; 95:S29. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44123=[""].join("\n");
var outline_f43_5_44123=null;
var title_f43_5_44124="CF supps bone health";
var content_f43_5_44124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary requirements relevant for bone health in cystic fibrosis, other than vitamin D",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Calcium*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Phosphorus*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Magnesium*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin K",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Recommended daily intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0 to 6 months",
"       </td>",
"       <td>",
"        200 mg",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        30 mg",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7 to 12 months",
"       </td>",
"       <td>",
"        260 mg",
"       </td>",
"       <td>",
"        275 mg",
"       </td>",
"       <td>",
"        75 mg",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 to 3 years",
"       </td>",
"       <td>",
"        700 mg",
"       </td>",
"       <td>",
"        460 mg",
"       </td>",
"       <td>",
"        80 mg",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4 to 8 years",
"       </td>",
"       <td>",
"        1000 mg",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        130 mg",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9 to 13 years",
"       </td>",
"       <td>",
"        1300 mg",
"       </td>",
"       <td>",
"        1250 mg",
"       </td>",
"       <td>",
"        240 mg",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14 to 18 years (boys)",
"       </td>",
"       <td>",
"        1300 mg",
"       </td>",
"       <td>",
"        1250 mg",
"       </td>",
"       <td>",
"        410 mg",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14 to 18 years (girls)",
"       </td>",
"       <td>",
"        1300 mg&nbsp;",
"       </td>",
"       <td>",
"        1250 mg&nbsp;",
"       </td>",
"       <td>",
"        360 mg&nbsp;",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adults (men)",
"       </td>",
"       <td>",
"        1000 mg",
"       </td>",
"       <td>",
"        700 mg",
"       </td>",
"       <td>",
"        400 mg",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adults (women)&nbsp;",
"       </td>",
"       <td>",
"        1000 mg&nbsp;",
"       </td>",
"       <td>",
"        700 mg",
"       </td>",
"       <td>",
"        310 mg&nbsp;",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     This table outlines the dietary requirements of calcium, phosphorus, magnesium and vitamin K for individuals with cystic fibrosis, each of which&nbsp;is relevant for bone health. Dietary requirements of vitamin D for individuals with cystic fibrosis are presented in a separate table.",
"    </p>",
"    <div class=\"footnotes\">",
"     * Dietary reference intakes (DRIs)&nbsp;for calcium, phosphorus and magnesium are the same as for a healthy population; these data are available at",
"     <a href=\"file://www.nap.edu\">",
"      www.nap.edu",
"     </a>",
"     . For these nutrients, the values shown for infants are adequate intakes (AIs), and the&nbsp;values for older children are recommended dietary allowances (RDAs).&nbsp;",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Vitamin K intake recommendations for patients with cystic fibrosis&nbsp;from: Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002; 35:246.",
"      <br/>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44124=[""].join("\n");
var outline_f43_5_44124=null;
var title_f43_5_44125="Contents: Photodermatology";
var content_f43_5_44125=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Photodermatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Photodermatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Photodermatoses",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/20/33092\">",
"           Melasma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/32/27142\">",
"           Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/54/23400\">",
"           Photoaging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/63/18426\">",
"           Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/62/20455\">",
"           Polymorphous light eruption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/39/21111\">",
"           Pseudoporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/27/30136\">",
"           Sunburn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Photoprotection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/42/33447\">",
"           Selection of sunscreen and sun-protective measures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Phototherapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/24/33160\">",
"           Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/9/26775\">",
"           UVB therapy (broadband and narrowband)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Porphyrias",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/42/5801\">",
"           Congenital erythropoietic porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/29/15834\">",
"           Erythropoietic protoporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/45/41687\">",
"           Hereditary coproporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/45/30421\">",
"           Porphyria cutanea tarda and hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/50/28458\">",
"           Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/19/28984\">",
"           Porphyrias: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/51/825\">",
"           Variegate porphyria",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-4CCFFCDDE7-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f43_5_44125=[""].join("\n");
var outline_f43_5_44125=null;
var title_f43_5_44126="Vertical talus";
var content_f43_5_44126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vertical talus deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vertical talus deformity (rockerbottom foot) in an infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44126=[""].join("\n");
var outline_f43_5_44126=null;
var title_f43_5_44127="Cystic hygroma CT IV";
var content_f43_5_44127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma involving right axilla and mediastinum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 276px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEUAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwlY9zALyTW5oXh3UdWnWO3gdgeM4r1zwf8HJXnhn1Bh5YwSte4aD4X03SIkS1t0BXHOKAPIPBvwgAihn1IZPUr6V63onhqx0qEJDCpx3xXQeWVOE5FNkAwADg+9ADVRF5VQMdMcUjc9enpT1C7MFsH09ajlZRzuGf5UAK/wAoHTHWomzgYOcnmoLm7hTbudeeOtI95Ai5dgAPyoAsglhtIyBUTqu4/KCvpVAa1ZNMES4TPTGas+crfNvBHrQBUv8ARNM1GMpc20bg+orh9d+FGkXgdrZPKcnPH8q9IBUkFScmlBIznrnqKAPmrxF8G9QhuA1niRSePYViP8MdeRXzCT0AxX1gWU7sjPemgRYOQMYoA+S7X4ba1MWYwMCpwc1tWHwg1OYIZGWME8g9a+kXa3QlV2Asc/WpV8ornIByOgoA8Q0r4MRksbqbHAxtH6122gfDuy0tfvb8cnPceld2zKDwDxwOKiiDGVueKAMW70KxuLJrea3RlJ9KoReAtDdZBJZRkkeldk0SlgD26fWpMImcHg0AcHJ8K9CeJikO0npz0rn9V+CtjdSL9lkaPue9ewoQV61cgCn7uPrQB4fF8EbVdp80tgYIPetCD4NaTE/zZBH869pWHPJPaopbYscg80AcDpngTSdPjjSOFSR3xXRJotjGgxEvA44rTeMqTgZps6HjbwKAKa6TaOioYEC/Sl/sWzDZECZznpUgm8nO7JJ701r5AzAuOnrQA2XRrNgf3KgY7Cq0nhywdiTCuG46VfS+jaXG/OBzVlJ42fIIz0NAHJah4E026Ur5YA6Diucu/hRYuD5ajce+OleqMMjio9xBxk4x260AeL3fweiUExHP1rA1X4P37oRDMGB6AivoISNy3TPHIqMzpnDEcdaAPlK++FOtWk4zAXUHOR3rkde8N6jaNiS0kjHOcqa+5PKjkQELn3NZmpaHZXsZS4t43X1K0AfAtzZzKRuQj6iqRjIPTmvsbxN8MdHuoWMaJE+cggYrynxB8I54pWbT2VlJOFPagDwwlgamiUE5Y4GK63VfAuq2RkMts+FOM461y89rJC7q6kFeMEUAKshjbETke9b+keJLu0VYbnZc25PzRyjIIrnEwpyR9aaz84oA63UdA0fX4/M0Y/Y9QIyYGPyN9DXBalp91pt09vexNFIpwQw61qxXciPujJDY6iumiuovEdg1nqmDdgYinPVT2B9qAPOCME0Vd1fTp9LvZLe5XDKeD6j1ooA/SCJVjJ7CozKApJG32Nc+Na3uVAJPT1okvBBatPdPsiHOSelAG80jEZBqhd6rbWrESSrvA6E15j4v+JUNqjW2mOHkPAbOazPh/Y33ia/a71O4ZkZsgZoA9ObV5bkFbaNmJIwRSjTr65beZDFzyK2rbTorGICILwOatLkqDkYoA5s6CZCPPmYkHORVm90rz7d4hJhduK1pQzHbnGeaYyMrkKcmgDgh4HMF1532gk7s9a2rzS7qOwkS3kJfGQc9K6BsE4foKj8wLubqo4oA4W51jWtHVWlgaeMHnA5xVWD4m2aPtvI3iYdQ3Y16HJJG2FZA2e2M1zPiTwHpmuRfPAI5TzvXigCld/EjRIk3faFOfSsuPx/FezbbUhlbsDnFeU+Kfhrqljrvk2qvJbsflavRPAfgNbO2Et0T5jY257UAdppH2i8bzCPmPt2rokkCSBWX8qy9Qv7bw9pYldlAAx+NcjZeOIriVpGkG0McAmgDtdU1Q26s23qcD2qTSLlZ4jKTgehrlItbg1hXSB1OOGINXNMmeK7Nup+XGTzQB0kurWfniF3CygZAJqeO7hm4UggDmvOtb0iWXWxdQytjncAe1adk88MLMzfIUzjvQB2qzrwgGR0PtW1aYaMetedaZeyqSWbcGPX0PWtix1xzK6cgKQvFAHdqvoaQj3/CsSDV2IC4Jap/7QZzjH1NAFuZST2qssqjCtnPvTDK7HAP0NMctnLj8/SgCKaFJWAJGT0+tZF5ozyTHbKyjFbDAMwxwRTidx68gUAYFvpMsFwHeVmXHH1q7bI6SSkE4960ArMDvOT2pyKCwPANAFeG6ZW8twdxrQilUlQDz3qvKsfmqdh4601Vw5KNjPOKANMorJj1FUrjTBKD5eQ3f3qSCbcdrMOelasa7VFAGBMt1pdsXdTIgHJHaq1jrdrexsYpFJHUZ5zXVOqupVgCp4IPevG/iN4J1TS5ptY8JtIyn5pbVeo9xQB1uqzKV3OCQBzXPwzm73u7AAjIFeU3HxN1awtBDqdqRKOCXGMVp6N4rtb2COXzgkjN9zOMUAenQW1vLbYlRZM9a5vxB8ONE1ze5t1ilf8AiQYq5p87FBLG/Hua3Le4Ah378seSKAPnLx18LLzRUea0BmgHoOa8ynsmiO11Ib3r7hlWO8tik4DIeoPpXg3xS8EeRcTX1hH+6DfMooA8MIK8YqaK4aMArw2etaM9iG3ZGGB+7VKWLyx93ketAGw9q3iTR3D4N9AuY/Vx6UVS8P3slpqUMqvtCtz70UAfZOozWWh2cs0rgBMnLeteB/EL4lXWoGWztjtgPHBrY+O2uXbSrapujTndjo1eGOZXmwcnPc0AbcF28jqwYseuSa9W+D+rXR1B4wxWPGfqa4nwh4Ye/h804CjrntXp3hzRBpbM0IIBUENQB6tcayIbQEuPMNc7P4uuI22qoYe3auZurq6uLtUBO3GAa19G03Dq06htwAJoA34vE8xMYdTlhn6VqLreWBY4wPzritbgkS4BtjkdMdMCq0sNw9xGZGO0dgeKAOuv/E8Ko5BLheCV7msVvFRe3kkgOQvGD/Os9oUhjCMBtI/irJvEjtoJVgGH5GD0oA6ODxysFzAt2uwMeS1eo6FKL+2SVBlGGRmvmTwnpt74u8VJYSBzCjcvj7uK+r9F0+PTNOgtY+kahc+vFAGbqVhGPnZAT6msC6u0jDptxtycjtXdzxrJGQ3T1ryzxDPNHqEsEaAoxxnPUZoA4v4mrdalp0f2Zn2xtkgHt6155BZz/ZZXywZeFxXt0ungWTrIMtjA9q4ucW1pdkPFkdcHjJ9aAPNtKvdS0O7MwZgmeRzg16f4S8R/2jCkzqVkA5J6msuU2d7qBjmjURnoR05q1pcVlDeNHBt4wBg0Adr57OVI6HJJPYVWNwzIQrcsPwqtNPFkR282BxkDtUST2sMqK8uSvOM0AaGnb1LiVGCFeOat21wpdkj4fdyDVQXimdCrDYV7fWnrNG0hdTg45460AdLpErO7Fxj0FbULY6DODXM6HqEQuTGxDOAK6JJ434AAGelAF6JsYxyRRI+5h1zUKyA9R2608ED72c9hQAEMxHH0qY/Lyo5FQbwpyPrTi7O2PyFADurjPQdfakRRjO7jPGOtBk2cnkt096VWjCnNAAQFYH+dKUJ5AGcc0NKrxYUYPanK4VVz3HWgBohA+YH5hV+G9VSI5TzjrVIFQAuOvP4VGSGlIY8D1oA3lYMMqcilrLjlKcxngdavW9wsy5HB7igDzT4z+BbbW9AmurS3UXUQ3naOSK+VptG1KCXdahyF9O1ffLqHUqwBUjBB714F8VvDcnh3UjqFhDnT7k/vAozsJoA8VsfHer6IiQXILRjnDV6H4V+KFlqsotpQIZGwBk1k33h218SWZV2Cz5IVgK8z8ReCNW0G4aSJGkiXlZI+eKAPrfTbkzQb8qVA45q3NBFeW/kyRK6tkEEV4d8HvFF1NE1jqEjF+MFjXtunXUexWVtxPBoA8X+IXw3ktp5L3T42MRydorx3WLRoHIcEEetfbjqLyMo6gqeK+cvj/oA0vUIrm2jAhmB+6OhoA8YjyJ1I6ZopyEGZM9jzRQB9efEXwjba7Zs8kWJVBwVFfO/irQk0qYIowy9eK+x7lN8Z3gYxmvlX4xSgeKJ4oW+Ut2oA7b4bQQy6KFbAdgBwOtdfHZyNGyRk4HBBrkPhdY3kdijspMbDj2rvraLfNIsLkEckGgCGHT4LePzJF9s+lTW93DBHIEPHOM9xRdyMsYQqSSuPrWBMJTwg6nBHpQBfaWOa4B35z19qku4DEpH3kPf0qnp1qxuCWPQc/WpJZ5URg75QnjNADZkIwMq2RyDVdLVbq5EKpvaRgvrxR53nEMjAAHBP+Fdn8MtFM88mo3C5jDZTPc0AdJ4J8I2fh+N5oolFxLyzY5rqmIVST0HNLXKeNNaFpF9mifDsOcHmgB2r6+rzvaWrAsBksK4m8lZ7/wA5yGYMeD3p+iQqbqSWV87hnJNVdYkiiud3mgknoO1AGrdXyLaqMDew5A7VyWqi3urv5k2uAAOO1aaypuWRiCAMfpVCW1SW9MruApOB/OgCidPjViDGCrD8elULCwjt7x22kRnHHetQeYmpghiUwR9BV2KISXIHAXuaAILa0tplwcoAeT601tNtopnkBZyDtye1TyRgSnZ9zrjvxT75bgrGIUGzdkj1+tAFBbGc3CSRbvLAJx/KpLx5khJiB3/dHFX7Od/MET43knj04olikjxv+Zs5Ax0oAwPDU+qWmqiS+BMQ9euK9T028ju1Bi6EdPSuWuVfEQMOS3fHI4qHTb6XTLxgQfIZ8c+poA9GhUFTyOO1KzAtgnmqtrL5iKw7jirAK9c80AKAwPQHFKpcvSOTgFCfTApHdlY4+poAlPykZyfShBk+v40zJfaxBJ6U9XC855+lADyhHGOPaggEn2HNNjctIxJyOuKasgbcAMUAWAFZRu4PQU7yoyvy/eHeoF/eEDOePWpolAJHPbNAE6IANuPpUkMe18ggE1Xkl24qaAl2DdPpQB478cPjPd+BNatdK0i1guLhkE0rS5wFzjAx34rpPAPxD8PfFPQWtH2QajtxNZSnkH1X1FfMf7R1/wDbfitqijkW4WH8hz/OvM7DUrvSr+K90+eS3uYWDJJGxBBoA+sJ9Fl0LW7m0MZ8jdujatFbVJSVCB1xghhkVxPgH4tR+Llg0/xAEj1NVwJuAJD/AI16VbxlY2ERByfvelAHG6v4RjimS40xfJlJyQveotB1bU9L1XyNUVjBkYY134hZHjLYY9zS6hpcGp2/lvsDZznHNAG5YXaTwCSEEqwyMdq8f/aNaUaLbDb1kOCfpW/beLIvDupy6deSqqRnqfSvNPi14wi8SP5Fsd0Ef3ff3oA8Y3kP070U2XKuwxiigD7k8Wam1npM8kUgBUcc818t39te+IfEsjoHkJf7wGa9F+J2u3E8Qht3YI4xgV0Hwa0m2Gm+dPGpuWzyfSgCfwvqK6No6WswAmVcsT+tbvhu6W7huJgMtgmuG+Ll0ljqERtyEJHzYHWt74dzmTQXk9Rjr1oA2pr192DGM9ge1ZT5klO/AbParVxFuaORnI5yBSRaeZrjcDxnrQBZiX7OxYsMBc9exqrNiaLC4bjGKvm3iWQo5zhe/cVn3cRW3ke3HzAgY9qAM61tXu7+CzgUmSV8Efzr33SLGPTdOhtYQAqLg47mvOfhVpUlxfS6ncj5Yhsj47nrXqROBQBS1e+j0+yeaRgOMD615Bqt3PqN40j4PJx9K6P4gar58y20bfu15yDXO2UO+RRkFccnvQBLawfu9xdguM4HpWfdCK4nZsdCAM1euGWJiik4VR171DcKUZFWMEEfzoArXIjUFI3yMcnsDVdmtkhX95uYnnBq80Cbl8xQA+QapRxWqF1ADMDhc96ALCQjaH9unfFWFjhG11cqc8ik2iK3DuAxYjK56VNEEcqyqPlOSPegBiRh5lKqQFOQfUVPcOqbTIDy2OP0qFL0C4ysfy56etTX5M0kYI2hufpQBXCwG8DEYkDcYNWMs7NgDj+dJa2yI5brxncfSrIkiLMo+8RxigCvNdOgQk5x19qzdRL3Z29FB+90rQnRXSXIzkHB9DVd7f5/mJaNlA2Dp9aAOr0i4aKKNXfKY61u7YyAQD61xdnL/qwOV9B2rsLciWJWHpQA8lSVAOCeRUqEd/1qt8vmAe1OTJ6dKAJZGGQFFO8rOCelOXBjORinRAMeTyeaAEJWPAJB9aQFGUYGGx3oJUnnkGldVK8EA0AOjiwAVI9RUhOwHPU9hUMWMDBxjvTy3VR1Pf1oAAQGy3Pt2q1asAmRnHUVQXBlHOOe9WpZlitZG5ACE5+goA+BvireG++IniGfs15IPyOK4qUnpW34nmFzr+pTg5ElxI2fqxrBmPNADre4ktp0mgcpIhypHavqn4P+LU8T6Esc8wF9bgK655b3r5NJ61veCvEVz4a123vrZyApwy54YUAfZd7NKjbSdqgZBp+lXkEkPD5ct1BzmuEm8WRa3pSXmnSZV1G5R1U45FR/DrW7dtRFtdS7fnyCaAMH432og1JLhMhpEBznrXkD3LLhSea+ivjtpcV3oMNzC43RHHXqDXzlLBz8x5FAEGojhXAwDRVm7jY2q46CigD6I1jwypje7u3xGOnHI4p/gjxDa2LvbIwG0Yq58bPEFtp+gmyjcC4c8BT0FeKeE5ZrjUYmSTblucmgDvviGy3+oB5j8pORXb+DYY7bSbZY/mjYdB3rivE5Ie2V8FTgEGvS/CdlH9ggZXVgvRc9KAL82nLIo5wcYHtVm2svsw2nDZySattGHk2twKswW5VQCdwBxz3oAx7xY3Yqo+ZhjPpXPXyXEDoijIbgD1Oa7WW2iDMzDn2rO0jTG1DxHCJBmGNgx/CgDvPCtgdO0O2hb/WEb2+pp/iK/Ww02Ry2GIwK0yQiEnAUCvMPGOtC+vzbRDcitj2oA568lFzO07Ekk5wa09Mt08lSMhtueO/tVWOBFUCRTl+S1bFsVijXCgKo60AZ06+XzKh2gc4GeKjj1CGRQFQMcY4rQup1dSrL8pznFZ9rFbxybkX5WPBx0oAZOwaRtyHH8I71ny2Sg78YYYII96uM0st2fRf5VWlkkRtpyHzx70ATW0flXK7juVlyQauqiI7tjg9/SqcQnkkicjgdhW1FBFKpWQ4buBxQBSiaETrF5eSfmBxWkI4HZYyADyRmlCW0KqyAZBxTp0eQttAz1BoAabSII4HBPb0qGKOANyOv6VMI5AhBcg471DFGd4PBX19aAG3UEBjO0n5hjFV4oDDblmU8Egg1fuR+7EqqBzg8ZzWZeXu2PBOMjp60AT6TG08xEXGDjmt5RNbgHd8o4xWF4duBNKzplccfWt65nXIXJbPSgC3bT+cSzAbhTxIQ7Y9KzIvMJ2KduemKtfMNucgjk0AaVpc5jw6jkVJCQrHJwO/eqdvIM7VwW5qcYw1AC7wJPUU09M9jUCO+87unapA2VG44z096ALMPzNjGFpZEJUkHpx9aiDFCuw5zwTVlQ2wEcZ60ARKrnjIzWH8Rr59L8DazdK+2RLV9pHY4xXQRI2eCM15B+0/r/wDY/gMadG/+k6jIIyM/wDk0AfH87lssxyTyTVCQ8nFW5T8uKpSHrQBGaTPNBpKAOy+H/iOTTNRW2lc/ZpjtIPavoPwP4B/twXV3ZzYKkEEdjXybG5R1IzkHIr7I/ZC8RJqekatYSNm5tyj89Sp4oA474g6VrdhaPaah5jRg/K3brXkV1Dgsrtg5r9Ate0Kx1uzkt72BHDgjJHIr5K+LPgA+Gbx2jctAxJU46e1AHmTIRbcj5aK39EsVvrCWP+JemelFAGVrmr3Os3hnvJWkOe9bPgqIz6zDHCMYOeawrDTZJIi4IPGcV6Z8ItH36msjxkknbnHSgDa8WQLCsDyZyOM+ld34HW3kt0KOfug4z3rkPHzodTayVSCq556Guy+HUCxWC/L8xUc0Adb5BJUg5qdFc8AHHHIpdhABB4J6VftUJjHTI4oAo/ZjJIVx261reG7BYZXlIO7GAasQ23GWXn2q9AUt4XZ2CIoJJPYUAeffGzx7b+D9Ihtt/wDpt4cRqOy9zXP+EUivdOhunJaRvm5Oe3Wvm/46eNW8X/Ee9ureTdYWjfZ7bB4Kr1P4nNe8/CPUIrvwhZSIQW2YJ96AO0uIcLnrj+VNQq8WG6VG10zGRFOT2HenWNvJsLN8pI6GgCK5jjZGQEKxHU1SjnjjEaJ8ye/WptStJJoHKNtb72f6VkQwypCm05IPXHU0AXy7NcqUVQCCGFTFEZWQoGK84HWqunoSVH8S53sffmrG9kuGZSNhGSaAJLGKcSAEDaRxn+taYVEYiQEkdMVVsp2ZcydOx9qlik8wsyke5oAlMkezIjOB7c1LIxxuxtpIZBxvUcDvUuxnXIxQBVcys2B096a8LqyAZxnJq28TON27B71D5UryjqFX+VAFG5kkViGPyA5Fc3rFyHuEiVQDyc+ldDqRYCUbRtxkEmuUNwtxeg7OVOPwoA6nRoTDZRlRtYDOPWtyELKg+UFutZVtMDANvJPOa0Ek8oBkBLjmgCxGTHMA6kEnIqxIybxgkk88UyKRJCHcfMOB9anjjWQ8gD3oARNqKWXqe1NV5CxJ6E0ku5GwuGAqCC73c98kAEUAXQNykEngVLCN0XzDmq6ZYZWr0UfQd6AH2ypG3zckdqmWTB6YFWY4VIyByBUN1GAgPTHQCgCDzRGzOxwB3NfF3x+8WHxP49uRDKJLGyHkRY6E/wAR/P8AlXuXx5+IH/CL6K+l2MinU7tSBg8xr618hTOWZmY5Y8k+poArTmqshqWU8moGNADSe1JRRQAo4Ne0fso67/ZHxatLWR9sOowvbEZ/ixlf1FeLVs+E9VfQvEularGSGs7mObI9Awz+lAH6dV578Z/DK674XmdF/ewgtx3ru7C6jvbG3uoDmKeNZUPqGGR/Ok1GEXFjcRMMh0Ix+FAHwtYFtMv2hbjnBBorVvbW31HxPfWynZKsjqufUE0UAYmnq8fEecgDrXqfwp1HF0YJQuQdwPQ1PZ+B43sslcSHkcYxWQlr/wAI/rsZ2ttB6jpQBseOoZZPEfnLnYeM+leg+B4yNPWQkYPrXBa/qMl40ckQHbnHauz8ASCWBoixJAyVoA7IrvOSePatWwiO4Ywec1mxLCoIOd2eTmt3SUDRh1+72oAu42jOK+cP2lfijJpVvN4c0aUrdTrieVW5jU9R9TXv/izV4dA8N6lqt0QsNpC0rH6V+cHijW7jX9dvdTu2LS3ErPz2GeB+VAGcDya94/Zy1Z7k3uil/mA82IZ/OvBAa6XwF4hm8M+KbHU4GI8twHA7qeo/KgD7Ft7c2crvK5JLYz6VqLdgSLGUySaqRXdvq2lW91bsCsyB1OapTzuuxmPzdAKANi5kjZAyDKA8g1hFikckgxuJyv09Kr/an3Y5xyaZLK07IuSqgYx2oAfK21wYn56tj1pkbOQscnIJz9c023aPa8bH5z971q5EYjCYzktjAPcigCWxQng9M4IrSSBgG28KPu+9c/NdS2xjWNSemCRW7aXHmwKQdhyBigB0AeN28wknOPpV4MCow+DVF3XeruTgccVYDx7N6YAP86ANG3ZTG2QSwPGO1RTuegG01HHKsK7lHzHnmnmcT5BAz04oA5rWjI6zI7Ddjg+grl7OAxo7JIHAbFdtqmltIHbJIb5celcRcWFxp1wQhJjJz+tAGpZajLHd+WcY4GO2PWuiivWAUAZzXP2MZSCV2jySSQxHSqkPiuwt7zyLmaNeOpP5UAdsmpQQyDzCFGevataK+hMJMbhlPTFeReJrw6yY49Kmyckkqe47Vb8P3Wqad+5ulLoBgmgDu5tT8yQmLj5sVatWjn5PUelZenwG4UMANrcj1rTFmbWPKnr1oA0YTtPXjOOtXUcg9c896y7RS6qW6e9XxuJyCMdT7UAbFpMXOMZIrhfjL47i8EaIk7x+ZdTZSFM9T6/Su50woxIAr5l/bGus+JtAtA3CWryEe5bH9KAPCPEut3mv6vPqWpTNLcTHJJPQdgKw5jnFTzNVOU56UARSHvULVI3PQ0wigBtFHeigAFSLyCB6VHT1NAH6HfAHWv7d+Efh25Zt0sdv9nk+sZ2/yAr0KvnL9i3WftHhLWtId8taXQmRfRXXn9RX0bQB8TfEe3bQfi7qiwjav2nev0PNFdR+0zpn2bxodQUHEyLk+4FFAHvP2OPySu0DjsK85+Jlmtvpjz28f75ec44xXq8YVVxXKeOLWO40u5RkyChOaAPnrQtZvr6+S3iUySKCSnqB1r1HwLdS2l2ZJARFIvHPNeWaLpEx1hprdyrox79K9I09plnXcMFAAQDQB6vp+LoOc/M3FdpZReTbRp3Arzj4cySzXEqSnoeBXptAHjP7Wmpvp/wguoo2Ia8uYrc/7uSx/wDQa+GXPNfZH7aUxTwBo8Of9ZqI4+iN/jXxs3WgBQcCpkPpVYHn61KtAH0f8BPFgv8ASJtGuZSLq3GYT3K+lejO0ru7uuAnb+tfIHh3WbrQ9Vhv7GQpLGfzHpX0x4K8VW3iW1ikMyrK2PMQHBzQB1Ua5Xc2BTZYJUG1Wzu6H1psckbXJiJOFHWpZ2bzIxGxIUE5NAFOGIPLvk+V+hqXLo8bI2BnnHU+1WnCSDcxAcjt2NQSR+QVwd2R+tAFidxMQZBgFcgD1qNZZ5JPMiUKinBpI5FlQROhGP4h2qe8DQaawiHPQUAW7S9iZMuQVDYz/KrLxNKnyHYoOfrXMW1tM5j2qcSDGAehrcImWBIiSWH8X9KALqyhMGRycelS2V0v29Y1XcOSa564aQSbZJAo9fx5rIn8VWunaiWeT5AxXPbFAHqsdt5g6HntXOeI7Gw0xf7Q16/gs7FOTvYDd7D1NcV4s+NdnoGm7rKEXF6w/dox4B9TXzf468b63401E3Wt3TOAf3cKcRxj0AoA9t8ffGvQTp0th4ZhmklOV88rtX0yO9eAX+tXN3cGR5WyTnrWSfagCgD6L+BCtqtq8qlpJITkrmvcdP00zh/Pi7ntXyJ8HfiDN4A8RrcvGbjTZ8Jcw99ufvL7ivuPw3qek+I9Fg1XQ7iO4s5xkMp6HuCOxHpQBkWem/Z2Cg8ZHarNxGrA9x0rTmUI/ByO+KzJX+ZsDBzmgCFhsXauAFHWoEnYTDBwMYIJp00qyKysCDnGRTYbUEr3yepoA6DSTmTIHGK+Lv2iPEq+I/ijqLRH/R7EC0jPrt6n8819a+M9ch8K+DtS1J2G6KFtgz95iMAfnXwhaWs2salNJISWlZpHY+pOaAMWZuarcFvm6VYu1CXDoOQpIzVNzzQAjkbuOgqM570p9qQ96AG0UZ4oAzQAdqcvtTaVetAHvn7Hmsiw+JdxYSSbU1CzZFB6FlIYfoDX2tX5x/B3UJNM+J3hm6jzkXsaEeoJwf51+jlAHjn7RGhrqHh2adE3TRDcvFFd54ztY7vTpo5huV1IwaKAISjLyDxWR4ibdYTqFLMVIArZGTuD9KoalwCoAoA8e0yyWyuZHZc7m/Wusskh2gsgYtxx6mo9X01bh38lgr5JxTvDs6JOtvLGS2QvPXPrQB2/grT3t715cHDda7qs7SYkS3j28MBzWjQB85/trsB4M8PqepvyR/3wa+PWr6t/bcuv9E8K2frLNMfyUV8pP196AGg808Uw8elKvFAEymt3wtrtxoWqQ3cDHajAsmeCK59TUqmgD608MeIrLxLbx3Fg48w43x9x7V2kUaJDMZE+bacEDp7V8deDfEdz4c1iC9tmO1D8yZ4I719feFdZtPEnh1b2xdXLphlz90+hoAzImjV2AyN7c5q9FghNoyufSsO61GKC5VXQgrkeuau2eoK6gKoII49jQBLdeaJwoXnG0kdqs3N0YtNLTDgLgH1pJlKhWX5vMXP+NRzwPPp0rS8IoyBQBUg1uNVXaBkjgD2om8RK0IynIPJz+tYkNsVg3DBCNgN6VM+nma3QDPJ/rQBz3iTW5ZpWMMh4IPB61zU1jc6jKixbndjk12ep+H02r5asr9x+prX8L6bDZuJpTzE3Gf4gKAPAviZoF9o13bNeROqSrlWIriMZ+tfVvxTu7DW7COylt0kYjKEdR9K4/wAIfDOxuLiKV7d3OQSG6CgDxTStA1TVZAmn2M87H+4hNbFz8PfFltEZJNCvdg6ssZOK+z9D0K00iyC29tHHgY+VcVtWcvl4LtjPY0Afnpc201pKYrqGSGQcFXUg16R8E/iHf+CNdESSNJplycTQE8Z/vAdjX1/q2ieH/EUDRarpdncbhgu0Q3fn1rzbWvgj4ahmNxpcLxMBkIHyM0Aeo6fqMOq2cV1buGSRdwxTLhHORiuV8FWc+kxG2dyVXG32rro7kFmGRmgCnJFtAwO3NOgmQMsYIz1q1gYcuM5Hesm6kSHdJkBlBbPtQB5B+0jrk7wW2jw58mTDvz39K81sNCFn4cedSVldSc/hXUeONSTxB4rEWwSCI7FI71L4gs5IdMW0DFHcfKDwDQB8/wB3aTLKxZTgk84rPnUqxWvUfHNnb6TolnvKm5lBPFeWztucn1oAjz0Jph+tOPTmm0AAooooAX8aOtJ60o9aAO3+Ddm998UvC8CDJN9Gx+gOTX6NmvhP9lDTxe/GGxkddy2tvLN9DtwP1NfdlAHO+IpkW2kD9ADRUOvxC5WaMjg5GfSigBrkbF9c1Q1QAwnHPrV5WBUqeR61UvUHlE56UAcldJ5Th/7vU4qJGgN1FLEP3isDxTdfvBFbyeXlmPBrndDvy12sUhIfd19KAPfNIYtaxkjBIBrQrI0C4EtqgGOFHStegD48/bTv/O8a6HZD/l3sjIfqzH/CvnM9a9W/aY1kaz8YNYaNg0VoEtVI/wBkc/rmvKGxQAg9TSg+mKQ0DtQA8HmpFJqEVID3oAsIfrzXZeBfHOpeFfOjtZD9nl+9GelcSDjBp6vwM0Ae26R43i1a9QTNtPTB969W0ueBUV0IZBj3r5ChmaJ90ZII7iu28K+Pb/S8RSt5sPcMaAPqnTJY54twwX25ANWbuNDa4K/KVORXBeAPFtjrPlCJ1WRVw4J/lXplxCBb7jgKenvQBysdrBKSqfKq889Kp3CTq58sZRVyB/WtuaSAu0SLyxGeKbJBHbRlRIGz6igDIhUCN5ZGBMQyc9TmsGe/ea68iINubBwo966C/sDNd29vATlxhgK7Xwj4KtbZo7q4j3SgdxQBy/hr4eyX8iXWo8ANuUHrivVtM0OzsIlWGFeBjOOtaUMSxqAoAAqXtQBUksoihAUZxXP6rpzxkMvTNdV0pksQkQg80AccH8phwQTV2OTzEy/JxUeu2TQsXXIWq9oGMCseg4NAEiQjcSq4NVI22XJVhwDmtaPBjJ6Y5yK526lkFw5wOCPyoA3ZJgYC2PlHWvM/HXiFLSB7eM5uJVICjrj1ruri+jh0eaWVtiopZj6AcmvlzVPGNvqPime4kmBjViI93SgDqPCumQpe/bJ8KxOQD1q54ztZ9Q1S0wxAICrj07VynhfU59Y8UiCJ8xk/Lg9s810vxA12Hw9cyOWX7RHGAq++OlAHkXxiuQ/idbON9yWsQU46Z715+Tg8Vf1S9kv7+a6nJMkrFiaoNQAz88/zpppxpp6UAFFFFABSr1FJTkFAH0r+xTp6y+J9f1BlyYbVYVPoWYH+lfXhOATXzd+xTp3leFtf1FlwZ7pYlPsq8/zr6NnOIm9cUAYF0fMMmTwWxRSNxuBHTvRQBA8bQS7XBA9arXEe9W3HA710urWvnwMyffUZFczMx8plwcng0AcfeQRfayr/AHSDiseOGOC9lZo+RwPf3rodagOd5XDY4J6CqtnaR3zriQCTA3D8aAPQvBUQfSIpuV3DgelaevTSWmjXtxDnfFCzjHsKfosQi02FAMcdKtXES3FvLDIMpIpRvoRigD8xteupb3V727nYtLNM7sT1JJNZjV0HjjS30TxfrOmS532t3JH6cBjiuePvQAUCjvSUAOHWnA8e1Mzj/GnDnvQBIKcDxkUwUozQBIrEf41KrZqCrZWEWqsrEyk8r7UAaWg6zdaReJNayMpB6Zr6h8FfEe21vRolvSsMsaDcCeuK+SEbByauxajcRACOVkA9DigD7CtZxPOHhcFCd2T6Vnar4isLGVlnnXcnQZ5r5rsPG2tWcPlw3bhcY61SXUr3UdRRppneR2AOTQB9heBp49SnW5QeYHXO7HSvW7SPZEuRzivOvg3pK2XhiyLrlymSSK9NHQUAFFFFABRRRQBW1C2F1bMh7jisCC1FurRPk+ldRWB4hdoI96DLdOKAEgj/ANHk45AxxXJ7JHuWTnlu/pXR208lho13d3xCRRoXZj2GOtfMHi3453U0d5b6Bb+SZCVW5c/Mo9QPWgDd/aA+IkdjYv4W0lx9sfH2mVD9xf7ufWvm1nIOe9SXdxLc3Ek9xI0k0h3O7HJJ9TVR2oA7L4b+IE0LXBeTnKopGPes7xl4hk1zVLi5kdm3sTXNBiD15+tNZutAA5561EevHApzHjjvTGoAQkU3NGeKKACgUUUAFPWm1Io4oA+6v2TrA2fwfs5GXBubiWb6jIA/lXrdzJztAPFcd8GbKPS/hV4btYCxAtFYk9ctyf511ZRiSeefWgDKun/eehzRVmeJQpLEZHUUUAbZAIIPSuc1W18iclB8jciujqvfwCeBlxk9qAOD1eN5YWJUY6VheHLINqUxRiFToT3rq7yzcrIrdemDWfodsYLl1K4yc5oA7vSsfZFAOcVbqhpjYUp+NX6APi79r3wp/Y/jy312GPFrq8fzkdBMgwfzGDXgL9a+8/2ovDi6/wDCbUJlTdc6Yy3kR74HDD/vkn8q+DX5Ax3oAjP0o+tB/lRyfegBRTuOhNIKXuPSgB3XqaO4pB3xyKXPTFAD80oP41GP1pw6e1AEit7j8akU1AKlQ9aAJ1967T4WeGrjxJ4rtLeFCYlcNI2OAK5vw5pU+ua5Y6XZqWnupViUAepr768I+AdH8I6JBa6ZbIsyKPNnx80jY5JNAG1odlHp9hDboPlRQtbCdKqWK7huJziruKAA0UVn3mq29sdrNlvQUAaFFZcOtWzthzt960kdXQMhBU9CKAHVWnhjkbMoHHPNWahvM/Z3K9QKAPKv2jNVmtPhfqsOn53zBY5CvVU3DNfD7n5fav0LW0sNXt7y11KNZYZFMbq3IIPWvhP4j+Hn8KeMtT0gkmOGTMLf3kPK/pQBzEje/wCVQs3elkPpUZOTQAE884zTSTQeopAPXpQAh7D9KMZOM09mQKgVcNzknpUZOetAC7cdxSEDJyaTn3xSCgB5CgUgAxxTaco/M0AOU+1a3hzTJdW1qzsIVJeeRUAA96zVTGK+mv2VPhrJd3B8VavAVt0O21Vhjee7D2oA+kfCNg+neHtOsh9yCFY8/QVqTqUycngcVcAAGAMCqGqNwig8mgDOvH3855NFNx8oAGT0ooA27S4S4iDKcnvU9cvYXZtZh/cY8100biRQy8g0AZ2qWqn96o9iKxPI2OH711rAMCCMg1z2qW7QzY6RnkGgBLe/8mRCwGO5roY3WRAyEFT3FcLeTDkZ465pmieKRZ6qLK8YC3kxsJ7GgDrfEtimp+HtTsZV3JcW0kRH1UivzO1Gzksb65tJlKvDIyEHtg4r9QuHXIOVI/MV8PftL+CJ9C8ZXGqW8R/s+8O8sBwr9xQB4gw5NA61I680zFACDjkU7tSd+eaDQAo984pRj86QGjvigB3580o9cUhpe9ACipY/0qIVPEpZgo+8e1AH0H+yD4YXUfGF7rtxHmLTYtkWRx5j8Z/AZr641C4igt2MjquRxk18s/CHxRb+BfCItkAN1O3mOPU9q3rzxlqXiG+VBIY4s52g0AfQuksr2ayJjDc1crmPh5LJJoCiYklXOCe4rd1K7SxtXmkI4HA9aAKWv6qljCUU5lYcDPSuLmuHmmJOSx5rM17UZri88wZzIeh7UqagsEgVh82Mc96ANTa0SjdkkjvV/RvEX2Gbybv/AFBIUH+7WYt55kW9hwo61jalM08gVQMZ6mgD2OGVJo1kiYMjDIIpLllS3kZzhQpJzXmfhrX7nRy0FwC9ooyGJ+7SfE3xukPhW4OmSoJpFIBznigDx7xP8S7/AEzxRqMNqw8rzGVcdMV5Z8StTbxK8WqOuZ1Gx2HVhTZC13el523Mx/Gunj8JrfaZ/ogyxXOKAPF3HzVGQM9a2/Eei3WlXbx3ETJg9xWIRQA3pTWPGacen0puO1ADc8ikP0pSKMUAAOAQOhptLS96AADNTIoGDSRRtI6oilnYgKq8kmvp34Jfs8y3Rttc8doY7cgSQ6b0Z/Qyeg9qAOP+AvwYvPG19Dq+uRSW3hyFgw3DDXRH8K/7Pqa+2rK1gsrWG2tIkht4VCRxoMBQOgFLa28NpbR29rEkMEShUjRcKoHYCpaAA8CsHUJ/OuRsb5QavaverbQ7QfnbtWApLNuXgnnBoA2LRFUBmGfrRVOGSTAUnFFAFRUwCcEkVq6PdBcxuSMnjNYVteRz58uVSD05qdnIYFThh70AdfVbUIRNbkEcjkVT07UQYgkx+YDrVi5vF2ERnk0AcTcxsPMUryCcHtXL6rZfbLqBVzvY9R2ruL8nceR9KyWSNH8xuF65oA7jQIJLfTII5XLlUHJ71i+PfCdt4q0e4sb2NZI5Vx05B7EVr+HtQg1CxU28ivs+VsHoa1KAPzh+JHgvUPBHiSfTdRiKp96GUjh07EVyRX8K/R/4i+A9G8e6K9hrMPzgfubhB88R9Qf6V8b/ABH+CfirwdNNLHaPqelLyt1brkgf7S9RQB5MV9qbj1qxIjRuUcFXHVSMEUwrx0oAi5HSnLgjnrS4pMe1AC4FFCqT0GTVyDT7iblUOPWgCoOvTNdZ4V0lJJFuLs7UU5wap2WnRRMu4eZJ2Fdr4e8KanrkqLboUhJwW6Ae9AGtbSWt7qccUeQgIAx2r0uHT4rbVIngB2njjv2rJ0bwXb6IXN5Jvm/hPY4r1LwBottqLCWcgsgB2elAHZeEZRFZRwouABisPx7qdwZxbBCsBH3sV3draQ2ybYkAHWodR0+3voik6KT2NAHkZVfPTLFto7/yqvcRh3kmydw6e1dF4j0WbTpi8a7k5IPpXKtKJGCDIMgORnoaAL0d15Vunz8bRk1W84yuxXovPNUWKwxNGWOxvkyan0qKe7vlt7KIy5+82OFoAmuo7nVLCS0s0ZrmTCLjsK1IfhJJc6E0V7eH7YwJHopr0HwtoaaXBvkUG5Ycn0roAecUAfBnxI8H614F1jydUizDJlobhfuOPY+tReCfGLafqUIuXzASN2fTNe9/tb6na/8ACKWWmKqyXrzeZgDJRQOv418ihHV8spAoA+19Y8D+HvH3hqC6tTE+9NyyJjIJHevmDx98KNd8NSTTLavNZqT86jPFdJ8DviRd+F9Yjsrpy+lzsFdSc7D6ivrx47LWtLEiBJoJlyDjIINAH5qshU4IwRTStfXPjr9ne11a5e70CYWcsh3GNuUz7eleN+J/gb400M5XTjexZ4e3O79OtAHk5Xn0puK6TUfCOvacub7SbuDBwS8ZFZh0u737fs0uTxjaaAM7FKq966Gz8J61eSKkOnzsW/2a9I+HHwZ1HVNdtf7biMForgyKepA7UAd9+y18Jop4ofF/iG3DANmxgkHHH/LQj+VfVNVdMt4LKwt7W1RY4IUEaKOgAFWSQBk0ALVLVNRg0+AvM4B7DPNPuLxI+FILVxPiW0lvpxI7EjsKAHyan9tmaVsnBwBVqOQOyZ7dKo2UUcUQjxhsd/WtOKIqynAJ9/WgCyhO4NjgUU1pCrAdB60UAfJ+h+PL21gjC3LfKe9dzpvxVxDG9z8zZ5wa+dEnkjOM9KvQXg24J4x60AfZXhLxVY61bRukyCQ9Vz3rqROoGOa+MPDmtzabdRzQSsoQgnnrX0N4I8f2WqJFFdyBZz2PegDv7zayFsjHeuB8fXsqWP2W1ciaU7RjrXoE5jaHIORjNcRc2sd3rsczIXSM9xQBN8LdPv8Aw/iW5mLxzL86E9PSvXopFljV0IINcF90gYwMdK09P1J7UBT9wDvQB1gNB54IGDVKy1G3u1/dSKT6Z5q3nOKAOG8bfCfwh4xV31TSoku2H/Hzbjy3B9eOv414trv7KuC76H4hOM/LHcxdB9RX1HkYqGaZUHLDNAHw34i+AXivRicfZ7pQcZibrXNL8LfE5cK9g4ycZr7t1HbOTuO7FYyRKG4XPegD5I0v4UayD+9tjxx+Ndzonwm1CRNtyRCOnSvdpp4bViH2gjkmrEE/2hleMfIec0AeQaX8JLK0vVeSQybcE7hXQTLaaAY7eBUXc3AHFdrqL/umMYO8+lcFceHbzV9Ua4nJRVOFGeooAWO0m1u9RmJEABA9j612fh7SH0e7W5gmbhcFexqPTdLNjbCNMcCta1WTaA/U9aAOsstSjnUbmCuexq+CCM1x6rgsOQc9a0bG/khxHMdyDvQBtTwx3EeyVAynjBrmb7wZp00/mRgxuSSMdK6aGWOVcowOPSn9s0AcWngW0LbZ3Lx+ldHo+jWWlQhLSIL/ALWOTV8HJOBTlHftQAvbPSuY8S+J47ENBakPce3am+LtXmhia1seJSOW9K4OSxfPmSMWlxyx75oA5nxFp39s3Ml3qI898gYPIAzV6z+Evh7UrPzGjyWHVT0NaTx5gaML14LVP4X1J9NuDbuC0O/PXpQB514x+DsGkadLe6dK5Ma7gpHeug+CnjaTTok0bV5DtBxEzfyr0fxFdwajZiGM538EV5rqHg+I3qXFqNhXnI9aAPoOGWOWMMjAjHBBqRFIPqPevL/Dup3lnsiLlkXrmurXxKseAyk9wcUAdDc2kFwu2eGORT2ZQaxbnwvpDuXNhbbs5z5YriL/AOLdtb662mm3fKsVLds10a+KPtcUbQjaWGelADb3SLeCXdFDGgHoKpRSC0nZ0UdcmpptRkb5Wyeeap3MkchKr1J5NAGqPEzLOIk9K0YdQuLjBZsLntXOQWkSlXZQG7fSt+DaI129v1oA0Iwjfe/Oq06bmyOlTKSEz0zTWAJzjjvQBS+zFnBxz2qdz5QyecCpgAFLMRgVz2v61FEHSNlyo5oAuXOpxKCrnFFeDeOfH5s/Ni0+QGU985ooA8UhvdL1aLEv+iXYGB/cY1Xu9PubXDMN0Z6OvIIrlA/PFa2n63c2m1Q++IcbH5FAGkl28Yx2rW0zWZra4jnifa6kdKoRXOm6ooH/AB63B/vH5Saiu9PurRssuU7MOhoA958MfFWQWf2fUCXYLjdnrWjpvxCtXuV3SbBnmvm9bmVGxzT11CZRw1AH2Oni/R2jDNexDjPJpZfGmh/Kn2uI7unzDke1fHJ1Kdh80h46c9KcuoSjGXJx056UAfYq6zZI3nWVwPmGeGrasvEVzIuIZ1JA6E18YWnia+twQk78+9dHofxDvtOl3NJvUkEhj1oA+r49Z1Vn/eMAmeo9K0VuHkQOxLGvGPCvxb0y4jVNRbyz0J7Cu/0zxnolyyrFextuwAAwoA6mUllIJOO+KhjU7T71CL61nHlxToTjPDetTJIqKF3AtjpmgDj9dhmvNZgtoiwjY5kb2rq4I0t7dIgMACkNvF5hl2jPSrEJDKRtyT0oAgjiDEkip44FUknGSaUnAUYxzmmXDlSMfd7mgCQhNvQdaRVCnPoKjtw0kTt2AyfYUAjbvB745oAf1kLk8CkZ89ORjNUru6EDqXyM+neraMsgUg8MOlAFy1uWtkDKTg9q37S5juI9y8HuD61zUrxxiMFsZHQ1XTVjYXK8jY520AdoB2FVdTuPs9sSvU8D60y1vY5Yg4YVk6tcmeTauCoNAGPcSeZKWlxuJrPu4y85OcK1XpAzE5Bz0FZ94s8JYryoNAFUQYOExtPJBrKSzmtpZm25BbIHpW5pgkkXfMvfFS3brDM28qAMDk0AUIEcRfMp3D9asrEAM7TnuO1YGt+ONL02YxO6O4649a5DUvi/BCmYYA7EHr2oA9OWMIyysNuT0p11cwxxBWZec4yeleC3nxU1G9GI2WJASSO9czqnjzULi38s3DDPUg0Ad74iGmv4qa7FxGOcsAeM11Vp8Q9C0+2aJ5d0iYXjmvmm51WSVy5lYk9c1WF2S5YnP40AfQWsfGOyQFbKBjIOpbpXHXnxe1OeTEMaKpPYV5abpWYlxTUnUEnFAHp0fxU1xZkJl3Kv8JrqtC+L+osUW4jBAPzYPOK8KFwd24VYjvXQhlO0+1AH1DpfxhgMSi5jye+K2Y/i1okyYabYcgCvk1dQYEEt83c0j3hZiRnPbHrQB9M+JPifZC3dbS4wxHBBryTxH49nuhLHbyOC/Vs1xtvaXdynmXBEMGOZJDgVBdajp1kCLNTcTD+Nvu/hQAl4sruJ71yiNzz1Iorn769lupN88hY9ueBRQBi0AmiigCVGPX3rQs9SuoWCrKxQHG1uRRRQBvWsguxumjj3E4JAxU5s4c52+veiigCtJZxBHYA5HTmqFxGE+7miigCLsKQk/rRRQA5XYHg1Yiv7mE5jlZcehoooA2LLxNq8H+qvZlxzwxratPH3iNfm/tGQn1NFFAHYaB8SvEkjKkt1G46cpXfaT411eZbfe8PzMQcJ1wPrRRQB2VhrF1OuZNmQOwrShu5JVG/b3HAoooAvWshK7eMN1HrimySMi7BjBOeaKKAIZlEvLgHmpbcDgdqKKAE1M7ckAEquRmuL1LUbgyxoWXAb096KKAOttbiRNIDK2CCRVW1v5i2CV4PpRRQBma7rt5asyxGPAHGVrj5PGmredIhaEqOeU/8Ar0UUAYmpeO9ah85YngUdBhOn61wOueNNcupMS3ZxnsMUUUAcXfajcyyl5JCzHnJrOkuJG6saKKAIPOfBG40zzGOBng0UUAAGQSc0pHyiiigBhGAfajcfXrRRQA5GOT7Gpo+XVSTgjNFFAGtYWMU7rv3c+hrodRtoNJsTLawoZNuQ0g3YoooA4a/1S7vpT9pmZh6DgD8KosxIHPWiigCORiKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan demonstrates a heterogeneous mass in the right axilla and right hemithorax, displacing the thymus to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_5_44127=[""].join("\n");
var outline_f43_5_44127=null;
